Archive for June, 2012

India Globalization Capital (IGC) MOU to Acquire a Mine in Inner Mongolia

BETHESDA, MD — (Marketwire) — 06/19/12 — India Globalization Capital, Inc. (NYSE MKT: IGC) (NYSE Amex: IGC), a company competing in the rapidly growing materials industry in India and China, announced that it has entered into an MOU to acquire an iron ore mine site.

IGC entered into an MOU to acquire a mine site adjacent to its existing iron ore mines in China. The acquisition gives IGC four sites from which to beneficiate low grade ore and process it into high-grade iron ore. Based on current pricing of $110 per ton, this site has estimated reserves of 66 percent grade iron ore valued at over $50 million. When complete, this acquisition will raise our combined estimated iron ore reserves on the four properties in Linxi, Inner Mongolia to approximately $600 million based on today’s pricing.

The purchase price for this property is $4.4 million. Based on our agreement, we have two years to deliver either 4.4 million shares of IGC stock at a market value of $1.00 per share or $4.4 million.

Ram Mukunda, IGC CEO, said, “With this modest beginning, our strategy is to consolidate properties in Inner Mongolia, which we believe will be accretive to IGC shareholder value. While this new property does not have a beneficiation plant, it is adjacent to our brand new state-of-the-art facilities and the logistics of moving raw material from this site to the beneficiation plant on our existing site is cost effective and relatively easy.”

“This represents a great vote of confidence in our model by the seller. Our joint goals are to complete the integration of Ironman; to execute operations to maximize the potential of our existing properties; and to continue to opportunistically acquire and consolidate several more properties. While we believe we can operate profitably at current iron ore prices, we also believe as pricing starts trending upward, the value that we create will be reflected in our stock. Until that time, we are seeing great value in many additional acquisition opportunities which we are studying,” Mukunda added.

Mr. Mukunda continued, “IGC has been working since the middle part of 2011 on the Ironman acquisition. As the acquisition was large compared to our float, it required a shareholder vote and then the filing of an S-1 to register the shares. Our effort to integrate Ironman has taken longer than we anticipated due to several factors including the heavy rains and flooding last year and the repair and maintenance work that followed. Currently, our team has been busy integrating the accounting systems, putting in place reporting and compliance processes, and negotiating with the government in Inner Mongolia to upgrade our status from a beneficiation company to a mining company. We have articulated to the government a strategy that includes being ecologically conscientious, respectful and helpful to the surrounding villages with a very unique ability to consolidate the other properties. The reception from the government has been very positive, as we are the only U.S. listed company working in that area.

“Given all of the issues that we have witnessed in many small cap Chinese companies over the last couple of years, we have been very focused on the many complexities of integrating our operations in China. After nearly a year of extremely hard work on this acquisition, we hope the integration will be completed in a few more weeks and we will be in a position to start production in all three existing beneficiation plants early in our July quarter. While we are unhappy about being behind schedule, it is critical that the governance and all the supporting controls, processes, and systems in China are fully implemented and capable of providing timely and accurate regulatory reporting and compliance. This provides a strong foundation for growth and also meets the standards and expectations of the local Linxi government before we fire up all three plants.”

Mr. Mukunda concluded, “Our financial results for our fiscal year, which ended in March 2012, and our first quarter for the current fiscal year will not be profitable due to the integration delays and investments we have made as discussed above. We however, remain confident that we can make up the lost time and post a profitable fiscal 2013. We plan on providing an update on our India operations prior to the end of this current quarter.”

About IGC:
Based in Bethesda, Maryland, India Globalization Capital (IGC) is a materials and infrastructure company operating in India and China. We currently supply Iron ore to Steel Companies operating in China and rock aggregate to the infrastructure industry in India. For more information about IGC, please visit IGC’s Web site at www.indiaglobalcap.com.

Forward-looking Statements:
Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words “may,” “will,” “should,” “could,” “expects,” “post”, “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential,” “proposed,” “confident” or “continue” or the negative of those terms. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of IGC concerning PRC Ironman with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond IGC’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, our competitive environment, infrastructure demands, Iron ore availability and governmental, regulatory, political, economic, legal and social conditions in China.

Factors that could cause actual results to differ, relate to the (i) ability of IGC to successfully execute on contracts and business plans, (ii) ability to raise capital and the structure of such capital including the exercise of warrants, (iii) exchange rate changes between the U.S. dollar, the Chinese RMB and the Indian rupee, (iv) weather conditions in China and India, (v) uncertainties with respect to the People’s Republic of China’s legal, regulatory and licensing environment, and (vi) ability of the Company to access ports on the coasts of India. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC’s amended Annual Report on Form 10-K for the year ended March 31, 2011 and Schedule 14A filed on December 9, 2011 with the Securities and Exchange Commission.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact Information
Investor Relations Contact:
Mr. John Selvaraj

Tuesday, June 19th, 2012 Uncategorized Comments Off on India Globalization Capital (IGC) MOU to Acquire a Mine in Inner Mongolia

NEI (NEI) Announces Agreement To Be Acquired By UNICOM Systems

CANTON, Mass., June 19, 2012 /PRNewswire/ — NEI (Nasdaq: NEI), a leading provider of server-based application platforms, deployment solutions and lifecycle support services for software technology developers and OEMs worldwide, announced today that it has signed a definitive merger agreement with UNICOM Systems, Inc. (“UNICOM”) and a new UNICOM subsidiary under which UNICOM, a global information technology company and part of the UNICOM group of companies, will acquire NEI for $1.45 per common share in cash. The transaction is valued at approximately $63.2 million. This price represents a premium of approximately 85.5% to NEI’s closing price of $0.78 on June 18, 2012.

The transaction is subject to customary closing conditions and the approval of NEI shareholders. The Boards of Directors of both NEI and UNICOM have unanimously approved the transaction and the NEI Board of Directors has recommended that NEI shareholders vote in favor of the transaction. The transaction is currently expected to close within NEI’s fiscal 2012 fourth quarter, the period ending September 30, 2012. Shareholders of NEI holding shares representing approximately 14.9% of the shares outstanding have entered into agreements with UNICOM under which they have agreed to vote their shares in favor of the proposed merger. Upon the consummation of the merger, NEI will become a private company, wholly owned by UNICOM.

Greg Shortell, President and Chief Executive Officer of NEI, commented, “This offer represents an attractive opportunity to deliver premium value and liquidity to NEI’s shareholders. I am excited about the potential for future growth with a strategic partner of UNICOM’s stature and global reach. This is an excellent opportunity to realize short- and long-term benefits for our customers, employees and technology partners.”

Under the terms of the definitive merger agreement, NEI is permitted to solicit alternative acquisition proposals from third parties through July 18, 2012 and intends to consider any such proposals. There can be no assurances that the solicitation of such proposals will result in an alternative acquisition transaction. It is not anticipated that any developments will be disclosed with regard to this process unless the Company’s Board of Directors makes an affirmative decision to proceed with an alternative acquisition proposal.  In addition, NEI may, at any time, subject to the terms of the definitive merger agreement, respond to unsolicited alternative acquisition proposals. The definitive merger agreement also contains certain break-up fees payable to each party in connection with the termination of the definitive merger agreement under certain circumstances.

NEI’s exclusive financial advisor on the proposed transaction is Needham & Company, LLC, and its legal counsel is Latham & Watkins LLP.

About NEI

NEI is a leading provider of server-based application platforms and lifecycle support services for software developers and OEMs worldwide. Through its expertise and comprehensive suite of solution design, system integration, application management, global logistics, support, and maintenance services, NEI is redefining application deployment solutions to provide customers with a sustainable competitive advantage. More than a decade of appliance innovation with the ability to provide physical, virtual and cloud-ready solutions makes NEI one of the most trusted software deployment partners in the industry. Founded in 1997, NEI is headquartered in Canton, Massachusetts, with facilities in Plano, Texas and Galway, Ireland, and trades on the NASDAQ exchange under the symbol NEI. For more information, visit www.nei.com.

Safe Harbor for Forward-Looking Statements

Statements in this press release regarding the Company’s future performance, including statements regarding the proposed sale of NEI and any other statements about the future expectations, beliefs, goals, plans or prospects of the Company or the Company’s management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The accuracy of these statements cannot be guaranteed as they are subject to a variety of risks, including but not limited to the inability to obtain stockholder approval for the transaction, the inability to satisfy closing conditions to the transaction, the loss of any key customer or customer product lines, the loss of key suppliers, our ability to retain key personnel and those other factors contained in the Company’s most recent Annual Report on Form 10-K for the year ended September 30, 2011 and the most recent Form 10-Q for the quarter ended March 31, 2012 under the sections entitled “Risk Factors” in such reports as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding the Company’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” and “would” or similar words. The Company assumes no obligations to update the information included in this press release.

Contact:

Hayden IR
Peter Seltzberg
646-415-8972
peter@haydenir.com
ir@nei.com

Tuesday, June 19th, 2012 Uncategorized Comments Off on NEI (NEI) Announces Agreement To Be Acquired By UNICOM Systems

Uranium Energy Corp (UEC) Demand for Uranium Expected to Rise as Japan Brings Two Reactors Back Online

NEW YORK, NY — (Marketwire) — 06/19/12 — The Uranium Industry has been showing signs of improvement recently as long term uranium prices last month increased for the first time since January 2011. Long term uranium prices jumped 2.5 percent to $61.50 from $60.00 according to Ux consulting. Demand for uranium is expected to grow as Japan over the weekend brought two reactors back online. The Paragon Report examines investing opportunities in the Uranium Industry and provides equity research on Cameco Corporation (NYSE: CCJ) (TSX: CCO.TO) and Uranium Energy Corp. (NYSE MKT: UEC) (NYSE Amex: UEC).

Access to the full company reports can be found at:

www.ParagonReport.com/CCJ

www.ParagonReport.com/UEC

More than a year after the Fukushima disaster, which triggered three meltdowns and halted all 50 reactors in Japan, Japanese Prime Minister Yoshihiko Noda has ordered the restart of two nuclear reactors. These will be the first time the Japanese government have used nuclear power since the incident. A decision on the remaining 48 reactors will likely be held off until a new nuclear regulatory agency is created. Japanese parliament is expected to pass a bill calling for a new nuclear regulatory agency as early as next week. “We will increase our efforts to restore the public’s trust over nuclear safety regulation and atomic energy administration,” Noda said, following a meeting with ministers.

Paragon Report releases regular market updates on the Uranium Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cameco recently announced that the agreement with AREVA Resources Canada Inc. to purchase AREVA’s 27.94 percent interest in the Millennium project for $150 million has closed. With the closing, Cameco’s interest in the Millennium project increases to 69.9 percent. The remaining 30.1 percent is owned by JCU (Canada) Exploration Company. Shares of Cameco are up over 14 percent year-to-date.

Of the 273,000 pounds produced in the third quarter 2012, Uranium Energy has sold 120,000 pounds at an average price of $52 per pound generating revenues of $6.2 million, and has 153,000 pounds available for sale in inventory with a market value of approximately $7.9 million. Shares of the company jumped nearly 22 percent Friday.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.ParagonReport.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Tuesday, June 19th, 2012 Uncategorized Comments Off on Uranium Energy Corp (UEC) Demand for Uranium Expected to Rise as Japan Brings Two Reactors Back Online

Cardium (CXM) Announces Launch Of New MedPodium Neo-Chill Nutra-App®

MedPodium Sponsors Magnolia Howell in Quest to Compete at the 2012 London Summer Olympics

SAN DIEGO, June 19, 2012 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that the Company will introduce its new MedPodium Neo-Chill Nutra-App® at the National Association of Chain Drug Stores (NACDS) Marketplace 2012.  MedPodium’s Neo-Chill Nutra-App® contains 200 mg Suntheanine®, a 100% pure L-theanine amino acid also found in green tea, which clinical studies have shown to promote an alert state of relaxation without drowsiness and to promote mental clarity and focus.*

(Photo: http://photos.prnewswire.com/prnh/20120619/LA26819)

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The Company will be exhibiting its MedPodium Nutra-Apps product line at the NACDS Marketplace (Booth 967) being held June 23 – 26, 2012 in Denver, Colorado.  The meeting is expected to be attended by approximately 230 retail companies, representing more than 145,000 food, drug, mass and specialty retail suppliers with $500 billion in annual buying power.  The Company will also be participating in the NACDS “Meet the Market” appointment program, which pairs suppliers and manufacturers with retailers for personalized one-on-one meetings.

Cardium also announced MedPodium’s sponsorship of Magnolia Howell, a member of Trinidad & Tobago’s national track team who is qualifying this week to compete at the 2012 Summer Olympics being held in London.  Magnolia graduated with a B.A. in Journalism and an International Business Certificate from Cal State Long Beach in 2007.  While at Cal State, she became one of the top sprinters in her Conference and achieved a 4×100 school record. She then became a member of and was sponsored by the VS Athletic Club; she also was part of the team that won the USA Track & Field (USATF) Club Championship. To read a recent interview with Magnolia and to learn how MedPodium Nutra-Apps assist in her training regime, please visit http://www.medpodium.com/index.php/Magnolia-Howell.

“Our MedPodium Nutra-Apps small capsule-based formulation allows for convenient pocket-sized packaging and is competitively priced for today’s performance-seeking and price-conscious millennial consumers.  We look forward to the launch of the new Neo-Chill™ product and our other MedPodium Nutra-Apps at the NACDS Marketplace conference this week.  The Marketplace provides us with the opportunity for personalized meetings with key food, drug, mass and specialty retail buyers,” stated Christopher J. Reinhard, Cardium’s Chairman and Chief Executive Officer.

Reinhard added, “We are also pleased to announce our sponsorship of Magnolia Howell and wish her the best of luck on June 24th and 25th during Trinidad’s National Open Championships to qualify and compete with her team at the 2012 Summer Olympics in London.”

About MedPodium Nutra-Apps®

MedPodium Nutra-Apps are small pharmaceutically-sealed, tasteless, easy-use capsules in pocket-sized packaging that are designed to address the unique needs of today’s millennial consumers.  Nutra-Apps provide premium science-based ingredients that have been characterized scientifically and shown to support an active lifestyle by enhancing energy, weight management, and relaxation*.  Nutra-Apps come in simple, “one-and-done” servings and are designed to fit comfortably in a pocket or purse for use anytime, anywhere. For more information about MedPodium Nutra-Apps, please visit www.medpodium.com.

About Cardium

Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations.  Cardium’s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform.  The Company’s lead commercial product Excellagen® topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations, which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that Neo-Chill™, Neo-Energy®, Neo-Carb Bloc® or other Nutra-Apps® can be effectively commercialized; that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities and that these products will be commercially successful or will effectively enhance our businesses or their market value; that results or trends observed in clinical studies or other observations will be reproduced in subsequent studies or in broader use; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that the Food and Drug Administration, the Federal Trade Commission or other regulatory agencies will not introduce additional or more restrictive regulations covering naturally-derived products such as those in our MedPodium product line; that our in-house or external product commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our co-development and strategic licensing arrangements will successfully and in a timely manner lead to the development, formulation, manufacture and licensing of products for Cardium’s MedPodium healthy lifestyle line; or that these or any other third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

*Note: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™, Generx®,Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linee®, Alena™, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

Suntheanine® is a trademark of Taiyo, International, Inc.

(Other trademarks belong to their respective owners)

Tuesday, June 19th, 2012 Uncategorized Comments Off on Cardium (CXM) Announces Launch Of New MedPodium Neo-Chill Nutra-App®

L&L’s (LLEN) Mine Consolidation in Guizhou – MOU to Acquire Lashu Mine

SEATTLE, June 18, 2012 /PRNewswire/ — L & L Energy, Inc. (NASDAQ: LLEN) (“L&L” or “Company”), a Seattle-based company with five-year track record of profitable coal operations in China, announced today, consistent with its consolidation strategy, the entry into an MOU to acquire the Lashu Mine (the “Mine” or “Lashu”) in HeZhang County, Guizhou Province.

The MOU, for 51% controlling stake in the Mine, is entered with Union Energy, previous owner of L&L’s Weishe Mine, also in HeZhang County.  The repeat transaction illustrates the confidence in the Company’s mining operations and enhances the reputation of the Company as consolidator of mining operations in the region.

Upon production, scheduled for fall 2012 and fully implemented within 2013, the Mine will produce low-sulfur, high BTU, anthracite coal at the approved annual production rate of 300,000 tons on 7.17 million tons of reserves, with potential expansion to 450,000 tons and beyond on reconnaissance resources of 20 million tons.

L&L will pay an earnest deposit of approximately $314,000 (RMB 2,000,000) and the remaining balance, which is being finalized, will be paid in installments over time in accordance with the definitive agreement.  Both L&L and Union Energy stand to profit from the enhanced mining operations supervised by L&L’s professional team.

L&L’s Chairman and CEO, Dickson Lee, commented, “The acquisition of the Mine is part of our consolidation strategy in HeZhang County. We are working with Union Energy and others to identify further opportunities.  We are organizing our mining assets in a focused manner, to maximize return to our shareholders. ”

About L&L

L&L was incorporated in 1995 by the Company’s Chairman and CEO. The Company has grown from a single employee to more than a thousand over the past 17 years. L&L has entered an expansion phase, seeking to consolidate mines in China and expand its sphere of business operations. Using its U.S.-style quality assurance processes, the Company is upgrading its mining portfolio and expanding its distribution network for strategic revenue growth.

Forward Looking Statements

The statements contained words that are not historical fact, including statements related to Company’s future performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve a number uncertainties. Actual results of the future events described in this document could differ materially. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contacts:
L&L Energy, Inc.
(206) 264-8065
ir@llenergyinc.com

SOURCE L & L Energy, Inc.

Monday, June 18th, 2012 Uncategorized Comments Off on L&L’s (LLEN) Mine Consolidation in Guizhou – MOU to Acquire Lashu Mine

Synthesis (SYMX) Announces Equity Investments Totaling $15.5 Million

–Strategic Cooperation with Hongye International Investment Group Co., Ltd.–

HOUSTON, June 18, 2012 /PRNewswire/ — Synthesis Energy Systems, Inc. (NASDAQ: SYMX) (“SES”) today announced that it has signed agreements with Hongye International Investment Group Co., Ltd. (“Hongye”) and Shanghai Zhongmo Investment Management Co., Ltd. (“Zhongmo”) for a total investment of approximately US$15.5 million in newly issued shares of SES common stock to support the Company’s SES China business.

Under the terms of the agreement, Hongye will receive 6,175,093 newly issued shares of common stock of SES at closing, representing an approximately 9.9% interest in SES, and Zhongmo will receive 4,177,335 newly issued shares of common stock, representing an approximately 6.7% ownership interest in SES. Hongye and Zhongmo will invest in SES through Qualified Domestic Institutional Investors (QDII) approved by China’s Securities Regulatory Commission. The purchase price per share is $1.50 and the transactions are scheduled to close by the end of July 2012. SES will increase the size of its Board of Directors from six members to eight, with two individuals to be appointed by Hongye, including Mr. Feng Gao, Hongye’s Chairman.

Hongye has a strong presence in the coal industry in Inner Mongolia and is looking to expand its coal to chemicals business there and elsewhere in China. This investment, in combination with SES’ unique coal gasification technology, provides SES and Hongye the ability to develop additional projects in China. Potential cooperation includes the expansion of SES’ Zao Zhuang Joint Venture project to produce glycol, the repurposing of SES’ Golden Concord project in Inner Mongolia to glycol, and Hongye’s current coal to chemicals project under development in Wuhai, Inner Mongolia. Glycol produced from coal is of strategic interest to Hongye, and SES’ technology can provide the low cost, efficient means to grow such a business.

“These agreements are an important step in advancing our current and future operations in China,” stated Colin S. Tam, Managing Director of SES China. “We are pleased that Hongye and Zhongmo have agreed to invest in SES, which we view as a further validation of the potential of our technology to unlock the value of low quality, low cost coals in China. We believe that our gasification technology represents a significant opportunity for Hongye and others to develop their coal to chemicals business and to add value to their coal mining operations in Inner Mongolia and other regions with abundant low quality and low cost coals. Chairman Gao’s track record in China business is impressive and we believe his entrepreneurial spirit and visionary leadership will accelerate the progress of SES in China.”

Robert Rigdon, President and CEO of SES, said, “With these investments from Hongye and Zhongmo, timed with the pending startup of our Yima Joint Venture project this summer, we believe that our SES China business is well positioned for near term growth.  This important strategic and financial accomplishment in China is indicative of the increasing interest we are seeing in our ability to add value to our partners’ and customers’ businesses.  SES is advancing additional similar initiatives outside of China around specific key business verticals such as transportation fuels, steel manufacturing, small scale power, and renewables.”

Chairman Gao of Hongye, said, “SES’ advanced coal gasification technology is strategically important and uniquely well suited to very low quality coals such as those in Inner Mongolia.  We believe it offers great promise to developing China’s future coal to chemicals and energy industries, and to advancing our growth plans in Inner Mongolia. We look forward to a strong and growing partnership with SES and SES China.”

Crystal Vision Energy acted as management advisors to SES, Roth Capital Partners acted as financial advisors and King & Wood Mallesons (PRC) and Porter Hedges LLP acted as legal advisors to SES.

About Synthesis Energy Systems, Inc.

SES provides technology, equipment and engineering services for the conversion of low rank, low cost coal and biomass feedstocks into energy and chemical products. Its strategy is to create value through providing technology and equipment in regions where low rank coals and biomass feedstocks can be profitably converted into high value products through its proprietary U-GAS® fluidized bed gasification technology, which SES licenses from the Gas Technology Institute. U-GAS® gasifies coal cost effectively, without many of the harmful emissions normally associated with coal combustion plants. The primary advantages of U-GAS® relative to other gasification technologies are (a) greater fuel flexibility provided by the ability of SES to use all ranks of coal (including low rank, high ash and high moisture coals, which are significantly cheaper than higher grade coals), many coal waste products and biomass feed stocks; and (b) the ability of SES to operate efficiently on a smaller scale, which enables the construction of plants more quickly, at a lower capital cost, and, in many cases, in closer proximity to coal sources. SES currently has offices in Houston, Texas, and Shanghai, China. For more information on SES and SRS, visit www.synthesisenergy.com or call (713) 579-0600.

About Hongye

Hongye is a diversified group and is one of the top 100 private enterprises in Inner Mongolia. Hongye operates in three major business areas – energy and natural resources, finance and bio-pharmaceuticals.  The major coal mine resources of Hongye are located in Wuhai City of Inner Mongolia.

About Zhongmo

Zhongmo is a private company principally engaged in providing financial and management consulting and advisory services.  Zhongmo specializes in providing consulting services to Chinese enterprises looking for investment and financing solutions domestically as well as abroad.

SES Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the early stage of development of SES, its estimate of the sufficiency of existing capital sources, its ability to successfully develop its licensing business, its ability to raise additional capital to fund cash requirements for future investments and operations including its China platform initiative, its ability to reduce operating costs, the limited history and viability of its technology, commodity prices and the availability and terms of financing opportunities, its results of operations in foreign countries, its ability to diversify, its ability to complete the restructuring of the ZZ Joint Venture, its ability to obtain the necessary approvals and permits for its future projects, the estimated timetables for achieving mechanical completion and commencing commercial operations for the Yima project as well as the ability of the Yima project to produce revenues and earnings, the sufficiency of internal controls and procedures and the ability of SES to effect the transactions with Hongye and Zhongmo, grow its business and generate revenues and earnings as a result of its proposed China and India platform initiatives, as well as its joint venture with Midas Resource Partners. Although SES believes that in making such forward-looking statements its expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected. SES cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Important Notice from SES

In connection with the proposed ZJX/China Energy transaction, SES has filed a preliminary proxy statement, and intends to file a definitive proxy statement, with the SEC and intends to mail the definitive proxy statement to the stockholders of SES. SES and its directors and officers may be deemed to be participants in the solicitation of proxies from the stockholders of SES in connection with the transaction. Information about the transaction is set forth in the preliminary proxy statement filed, and will be set forth in the definitive proxy statement to be filed by SES with the SEC.

You may obtain the preliminary statement and, when available, the definitive proxy statement, for free by visiting EDGAR on the SEC website at www.sec.gov. Investors should read the definitive proxy statement carefully before making any voting or investment decision because that document will contain important information.

Monday, June 18th, 2012 Uncategorized Comments Off on Synthesis (SYMX) Announces Equity Investments Totaling $15.5 Million

China Finance Online (JRJC) Forms Exclusive Partnership with Baidu on Mobile Web App

BEIJING, June 18, 2012 /PRNewswire-Asia/ — China Finance Online Co. Limited (“China Finance Online”, “the Company”) (NASDAQ GS: JRJC), a technology-driven, user-focused market leader in China in providing vertically integrated financial information and services including news, data, analytics, securities investment advisory and brokerage-related services, today announced that its flagship portal site Stockstar.com (“Stockstar”) has entered into an exclusive partnership with Baidu.com (“Baidu”) on a mobile web application to provide financial information services.

Under the partnership, Stockstar and Baidu have launched a mobile web application integrating Stockstar’s proven financial information services with leading internet technologies. The application allows users to access a variety of information on companies traded on the Shanghai Stock Exchange and the Shenzhen Stock Exchange.

Pioneered in introducing HTML5 technology into developing financial information services, the application greatly enhances user experience of searching for and digesting financial information on mobile devices through a highly user-friendly system interface and lower requirement on data usage. Users are able to quickly and conveniently access information including company profile, trading data and charts, and company news without having to install any local application or account registration.

The web application went live in June 2012. Through the application, smartphones running on Google Android and Apple iOS operating systems are now able to access financial information by inputting company name or ticker into Baidu’s search engine.

Mr. Zhiwei Zhao, Chairman and CEO of China Finance Online, commented, “This partnership speaks volumes about our leadership in financial information services and technologies. Stockstar is one of the most established financial portal sites in China with a proven track record in data processing, website optimization, and client development. As more Chinese are spending more time seeking market intelligence online, extending our competitive advantages to the mobile internet market is a natural choice.

“Meanwhile, we are excited to provide our timely, reliable and robust financial information services to Baidu users. Baidu is the No. 1 website in China with the largest user base and highest traffic rank. I am optimistic that by building on Baidu’s powerful and far-reaching platform we will be able to expand our potential users and provide them with a better mobile experience in accessing financial information that is faster, cheaper and more streamlined,” Mr. Zhao concluded.

About China Finance Online

China Finance Online Co. Limited is a technology-driven, user-focused market leader in China in providing vertically integrated financial information and services including news, data, analytics, securities investment advisory and brokerage-related services. Through its flagship portal sites, www.jrj.com and www.stockstar.com, the Company offers basic software and information services to individual investors which integrate financial and listed-company data, information and analytics from multiple sources. Leveraging on its robust internet capabilities and registered user base, China Finance Online is developing securities investment advisory and over time wealth management services. Through its subsidiary, Genius, the Company provides financial database and analytics to institutional customers including domestic brokerages and investment firms. Through its subsidiary, Daily Growth, the Company provides securities brokerage services in Hong Kong.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, this release contains the following forward-looking statements regarding:

  • our product upgrade and strategic transformation initiative;
  • cost-cutting initiative and its effect on efficiency and operational performance;
  • potential business consolidation amidst the new regulatory environment;
  • the market prospect of the business of securities investment advisory and wealth management; and
  • the transition period to adapt to the new compliance requirements.

Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which risks and uncertainties include, among others, the following:

  • the changing customer needs, regulatory environment and market condition that we are subject to;
  • the uneven sector-growth of the Chinese economy that could lead to volatility in the equity markets and affect our operating results in the coming quarters;
  • the unpredictability of our strategic transformation and upgrade;
  • the competition we are facing in the new business of securities investment advisory and wealth management;
  • global macroeconomic uncertainties;
  • wavering investor confidence that could impact our business; and
  • possible non-cash goodwill, intangible assets and investment impairment may adversely affect our net income.

Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F under “Forward-Looking Information” and “Risk Factors”. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact:

Julie Zhu
China Finance Online Co. Limited
+86-10-5832-5288
ir@jrj.com

Shiwei Yin
Grayling
+1-646-284-9474
shiwei.yin@grayling.com

SOURCE China Finance Online Co., Ltd.

Monday, June 18th, 2012 Uncategorized Comments Off on China Finance Online (JRJC) Forms Exclusive Partnership with Baidu on Mobile Web App

Vringo (VRNG) Announces Memorandum Opinion & Order

On June 15, 2012, the Court issued a Memorandum Opinion & Order relating to the Markman hearing on June 4, 2012 in connection with the lawsuit captioned I/P Engine, Inc. v. AOL Inc. et al., Civ. Action No. 2:11-cv-512, filed in United States District Court for the Eastern District of Virginia, Norfolk Division on September 15, 2011.

I/P Engine, Inc. is a wholly-owned subsidiary of Innovate/Protect, Inc. Vringo has entered into a definitive merger agreement with Innovate/Protect, Inc.

A copy of the Memorandum Opinion & Order is available on the Public Access to Court Electronic Records (PACER) electronic public access service at http://www.pacer.uscourts.gov/, and will be filed by Vringo, Inc. with the U.S. Securities and Exchange Commission.

About Vringo, Inc.

Vringo (NYSE Amex: VRNG) is a provider of software platforms for mobile social and video applications. With its award-winning video ringtone application and other mobile software platforms, including Facetones™, Video Remix and Fan Loyalty, Vringo transforms the basic act of making and receiving mobile phone calls into a highly visual, social experience.

Vringo has entered into a definitive merger agreement with Innovate/Protect, Inc. For more information, visit: www.vringoIP.com.

Vringo’s video ringtone service enables users to create or take video, images and slideshows from virtually anywhere and turn it into their visual call signature. Vringo’s Facetones™ application creates an automated video slideshow using friends’ photos from social media web sites, which is played each time a user communicates with a friend using a mobile device. For more information, visit: www.vringo.com and www.vringoinc.com.

About Innovate/Protect, Inc.

Innovate/Protect, Inc. is an intellectual property firm founded in 2011 whose wholly-owned subsidiary, I/P Engine, Inc. holds eight patents that were acquired from Lycos, Inc.

Important Additional Information Will Be Filed with the SEC

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities of Vringo, or Innovate/Protect or the solicitation of any vote or approval. In connection with the proposed transaction, Vringo filed a Registration Statement on Form S-4 with the SEC on April 6, 2012, subsequently amended on May 17, 2012, June 1, 2012 and June 12, 2012, which includes a preliminary proxy statement/prospectus of Vringo. These materials are not yet final and will be further amended. The proxy statement/prospectus contains important information about Vringo, Innovate/Protect, the transaction and related matters. Vringo will mail or otherwise deliver the proxy statement/prospectus to its stockholders and the stockholders of Innovate/Protect once it is final. Investors and security holders of Vringo and Innovate/Protect are urged to read carefully the definitive proxy statement/prospectus relating to the merger (including any amendments or supplements thereto) in its entirety when it is available, because it will contain important information about Vringo, Innovate/Protect and the proposed transaction.

Investors and security holders of Vringo will be able to obtain free copies of the proxy statement/prospectus for the proposed merger (when it is available) and other documents filed with the SEC by Vringo through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders of Vringo and Innovate/Protect will be able to obtain free copies of the proxy statement/prospectus for the proposed merger (when it is available) by contacting Vringo, Inc., Attn.: Cliff Weinstein, VP Corporate Development, at 44 W. 28th Street, New York, New York 10001, or by e-mail at cliff@vringo.com. Investors and security holders of Innovate/Protect will also be able to obtain free copies of the proxy statement/prospectus for the merger by contacting Innovate/Protect, Attn.: Chief Operating Officer, 380 Madison Avenue, 22nd Floor, New York, NY 10017, or by e-mail at info@innovateprotect.com.

Vringo and Innovate/Protect, and their respective directors and certain of their executive officers, may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the agreement between Vringo and Innovate/Protect. Information regarding Vringo’s directors and executive officers is contained in Vringo’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which was filed with the SEC on March 30, 2012, and in the proxy statement/prospectus. Information regarding Innovate/Protect’s directors and officers and a more complete description of the interests of Vringo’s directors and officers in the proposed transaction is available in the proxy statement/prospectus.

Forward-Looking Statements

This press release includes forward-looking statements, which may be identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our ability to complete our previously announced proposed merger with Innovate/Protect, Inc., our ability to raise capital to fund our operations, the continued listing of our securities on the NYSE Amex, market acceptance of our products, our ability to protect our intellectual property rights, competition from other providers and products and other factors discussed from time to time in our filings with the Securities and Exchange Commission. Vringo expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Monday, June 18th, 2012 Uncategorized Comments Off on Vringo (VRNG) Announces Memorandum Opinion & Order

Extorre (XG) Enters Into Agreement for Sale to Yamana

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 06/18/12 — Extorre Gold Mines Limited (NYSE MKT:XG)(NYSE Amex:XG)(TSX:XG)(FRANKFURT:E1R) (“Extorre” or the “Company”) is pleased to announce today that it has entered into a definitive agreement (the “Agreement”) with Yamana Gold Inc. (TSX:YRI)(NYSE:AUY)(LSE:YAU) (“Yamana”) pursuant to which Yamana will acquire all of the issued and outstanding common shares of Extorre (“Extorre Shares”) by way of a statutory plan of arrangement (the “Arrangement”) under the Canada Business Corporations Act.

Transaction Details

Under the terms of the Agreement, each Extorre shareholder will receive in exchange for each Extorre Share held, $3.50 in cash and 0.0467 of a common share of Yamana (“Yamana Share”). Each holder of an Extorre stock option (an “Option”) shall be entitled to receive, upon the exercise of such Options, Yamana Shares based upon a share exchange ratio of 0.2648 of a Yamana Share for each Extorre Share which would have been issuable upon exercise of such Options prior to the effective date of the Arrangement.

Based on the closing price of the Yamana Shares on the Toronto Stock Exchange (“TSX”) of $16.36 on June 15, 2012, the last trading day before announcement of the Arrangement, the implied transaction price of $4.26 per Extorre Share represents a premium of approximately 54% over the 20-day volume weighted average price of the Extorre Shares on the TSX for the period ending June 15, 2012. The transaction value on a basic shares outstanding basis is approximately $414 million.

Completion of the Arrangement is subject to certain customary conditions, including receipt of all necessary court, shareholder and regulatory approvals. The Agreement also provides for, among other things, customary non-solicitation covenants, a “right to match” in favour of Yamana in the event of a superior proposal and the payment by Extorre to Yamana of a $15 million termination fee should the Arrangement Agreement be terminated in certain circumstances.

The special meeting for Extorre shareholders to approve the Arrangement is expected to occur on or about August 15, 2012. The Arrangement must be approved by 66 2/3% of the Extorre Shares voted at the meeting.

Yale Simpson, Co-Chairman of Extorre commented on the Arrangement as follows:

“We are pleased to be entering into this transaction with Yamana. Extorre’s share price has suffered dramatically over the past few months due to a number of factors including: global political and economic uncertainty impacting credit markets; a broad sell-off of all junior non-producing gold companies; concerns with respect to share dilution arising from a decision to develop the Cerro Moro project; and a series of events that have raised the perceived investment risk in Argentina.

Management and the board of directors of Extorre diligently examined all of the available options to finance the Cerro Moro project to production, but given current market conditions, whatever financing mix was chosen, the result would be a serious erosion of the project returns. In conclusion, if Extorre were to lock into the current fiscal/operating environment, the value of the Cerro Moro project to shareholders would be significantly diminished. Aside from this, management did not believe shelving a development decision for any length of time would be viable.

The Cerro Moro project fits very well into Yamana’s portfolio and Yamana has both the operational experience in Argentina and financial strength to develop the project on a timely basis. Given the full set of circumstances faced by the Company, the board of directors of Extorre was unanimous in concluding that this transaction represents a good outcome for all stakeholders.”

The board of directors of Extorre, based on the recommendation of its special committee, unanimously determined the Arrangement to be in the best interests of the Company and recommends that the Extorre shareholders vote in favour of the Arrangement.

Voting and Support Agreements

Each of the senior officers and directors of Extorre, representing, in aggregate, approximately 7.4% of the issued and outstanding Extorre Shares, has entered into a voting and support agreement with Yamana, pursuant to which, among other things, they have agreed to vote their Extorre Shares in favour of the Arrangement, not to solicit other transactions and to otherwise support the Arrangement.

Advisors

Extorre’s financial advisor for the Arrangement is Canaccord Genuity Corp. and its legal advisor is Gowling Lafleur Henderson LLP. The financial advisor to the special committee of independent directors of Extorre is Gryphon Partners Canada Inc., a wholly owned subsidiary of Standard Chartered Bank, and its legal advisor is Blake, Cassels & Graydon LLP. Each of Canaccord Genuity Corp. and Gryphon Partners Canada Inc. delivered oral opinions that the consideration to be received by the Extorre shareholders is fair from a financial point of view to the Extorre shareholders other than Yamana and its affiliates.

About Extorre

Extorre is a junior mining company with exploration and development stage precious metals projects in Argentina, the most advanced of which is its Cerro Moro project in the province of Santa Cruz. Extorre Shares are listed on the TSX and NYSE-MKT Exchanges under the symbol XG. You are invited to visit the Extorre’s website at www.extorre.com.

About Yamana

Yamana is a Canadian-based gold producer with significant gold production, gold development stage properties, exploration properties, and land positions in Brazil, Argentina, Chile, Mexico and Colombia. Yamana plans to continue to build on this base through existing operating mine expansions, throughput increases, development of new mines, the advancement of its exploration properties and by targeting other gold consolidation opportunities with a primary focus in the Americas.

EXTORRE GOLD MINES LIMITED

Mr. Yale Simpson, Co-Chairman

Safe Harbour Statement – This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward-looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements. Such factors and assumptions include, among others, the effects of general economic conditions, the price of gold and silver, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations and misjudgements in the course of preparing forward-looking statements. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.

Known risk factors include risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in metal prices; title matters; uncertainties and risks related to carrying on business in foreign countries; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain of our officers, directors or promoters of with certain other projects; the absence of dividends; currency fluctuations; competition; dilution; the volatility of the price of Extorre Shares and volume traded; tax consequences to U.S. investors; and other risks and uncertainties, including those relating to the Cerro Moro project and general risks associated with the mineral exploration and development industry described in the Company’s Amended Annual Information Form for the fiscal period ended December 31, 2011, dated March 30, 2012 filed with the Canadian Securities Administrators and available under the Company’s profile on SEDAR at www.sedar.com. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. We are under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

Cautionary Note to United States Investors – The information contained herein and incorporated by reference herein has been prepared in accordance with the requirements of Canadian securities laws, which differ from the requirements of United States securities laws. In particular, the term “resource” does not equate to the term “reserve”. The Securities Exchange Commission’s (the “SEC”) disclosure standards normally do not permit the inclusion of information concerning “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” or other descriptions of the amount of mineralization in mineral deposits that do not constitute “reserves” by SEC standards, unless such information is required to be disclosed by the law of the Company’s jurisdiction of incorporation or of a jurisdiction in which its securities are traded. U.S. investors should also understand that “inferred mineral resources” have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. Disclosure of “contained ounces” is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in place tonnage and grade without reference to unit measures.

NEITHER THE TSX NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE

Contacts:
Extorre Gold Mines Limited
Rob Grey
VP Corporate Communications
604.681.9512 or Toll-free: 1.888.688.9512
604.688.9532 (FAX)

Extorre Gold Mines Limited
Suite 1660, 999 West Hastings St.
Vancouver, BC
Canada V6C 2W2

Monday, June 18th, 2012 Uncategorized Comments Off on Extorre (XG) Enters Into Agreement for Sale to Yamana

FluoroPharma (FPMI) CEO Provides Shareholders With a “State of the Union” Communication

Shaping the Future of Molecular PET Imaging to Enable Earliest Possible Diagnosis of Disease – Even Before Symptoms Appear

MONTCLAIR, N.J., June 18, 2012 (GLOBE NEWSWIRE) — FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced today the release of a company overview as presented by FluoroPharma’s President, CEO and Chairman of the Board, Thijs Spoor. This second “State of the Union” address serves to provide shareholders with a perspective on the company, its evolution and future potential.

Mr. Spoor began the communication by stating, “Our company vision is clear, our financial position is sound, our promising product portfolio is on track and our company is led by a highly qualified team with significant and directly applicable experience in the successful development of radiopharmaceuticals. Our comprehensive technology platform was developed by scientists at the Massachusetts General Hospital and we are well positioned to capitalize on its superior technology.”

“As we advance our business model, we recognize the importance of keeping shareholders informed, and it is with this intention that I present this to you today.”

Our Business Outlook

FluoroPharma is looking to capitalize on the growth of PET in cardiac diagnostics. In development are three novel cardiac PET radiopharmaceuticals, two of which are in clinical-stage and have advanced to phase II clinical. The third candidate is in the pre-clinical, early development stage.

FluoroPharma’s products are aimed at improving overall patient care via improved disease detection and could potentially provide greater diagnostic accuracy compared to currently employed nuclear imaging agents and modalities, increase the use of PET in cardiac imaging, and help reduce the number of unnecessary diagnostic and therapeutic procedures.

In the U.S., there are estimated to be more than 2 million PET imaging procedures done per year according to Biotech Systems – although the vast majority of these scans are for the diagnosis of cancer. PET is becoming more established in the cardiac setting as several factors have led to a shift in favor of PET for the diagnosis of cardiac disease.

Roughly one-third of all Americans are estimated to have some form of cardiovascular disease, with approximately 13 million people suffering from coronary artery disease. Cardiovascular disease is the number one leading cause of death in the U.S., claiming almost one million lives per year. People with cardiovascular disease typically have an accumulation of plaque within the walls of the coronary arteries (i.e. – atherosclerosis) that supply the myocardium (heart muscle) with oxygen. Known as coronary artery disease (CAD), the condition is progressive and can result in severely reduced supply of blood to the heart (i.e. – myocardial ischemia or ischemic heart disease). Acute coronary syndrome (ACS) is a term used to describe symptoms of the disease, such as chest pain or a heart attack. As these symptoms may not be present until the disease has progressed to an advanced stage, barring a reliable diagnosis and appropriate intervention, CAD is often fatal. Cardiac imaging is used to diagnose CAD and to determine the presence and severity of ischemic heart disease and the related risk of suffering a heart attack. It is also used to help determine the most appropriate course of treatment.

Our Portfolio

FluoroPharma’s initial focus is the development of innovative positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). The FluoroPharma team is advancing two products in clinical trials for the assessment of cardiac disease. These first in class novel diagnostic agents have been designed to rapidly target myocardial cells. Other products in the pipeline include imaging agents for detection of a bio-marker associated with Alzheimer’s disease and imaging agents that could potentially be used for imaging specific cancers.

CLINICAL PROGRAMS: FLUOROPHARMA’S DEVELOPMENT PIPELINE

CardioPET: Cardiac Viability

The Company has advanced CardioPET, a Flourine-18 labeled tracer, to Phase II. CardioPET, FluoroPharma’s first in class diagnostic agent, is being developed for the detection and assessment of acute and chronic forms of coronary disease that affects millions of patients worldwide. CardioPET, a novel molecular imaging agent is a perfusion and fatty acid uptake indicator, which is designed to be used as a cardiac imaging agent that may be a more specific alternative to currently available diagnostic tests. Its pharmacokinetic characteristics could be especially valuable in patients who are unable to exercise.

CardioPET is designed to provide metabolic information in addition to perfusion in the evaluation of the heart. FluoroPharma believes that CardioPET may be used for cardiovascular assessment not only through perfusion evaluation but also through its ability to specifically identify heart tissue that has suffered an acute episode of ischemia (insufficient blood flow), but is still viable. Identifying such myocardium, also referred to as hibernating or stunned myocardium, from non-viable scar tissue is important because it is well documented that revascularization in patients with substantial areas of stunned myocardium results in improved left ventricular function and survival. The company believes that CardioPET, if approved, may have significant advantages over currently utilized tests in cardiac evaluation, by including assessment of cardiac viability.

BFPET: Myocardial Perfusion Imaging

Also advancing to Phase II is FluoroPharma’s BFPET, a novel blood-flow imaging agent for myocardial perfusion imaging with the potential for measuring cardiovascular blood flow. BFPET, a Flourine-18 labeled tracer, has been designed to enter the myocardial cells in direct proportion to blood flow and cell membrane potential. These are two of the most important physiological indicators upon which adequate blood supply to the heart depends. BFPET has been designed to differentiate among those cells of the myocardium that may be ischemic, infarcted and those that are healthy.

Ischemic and infarcted cells should take up less BFPET than healthy myocardial cells. The signal emitted by BFPET should be inversely proportional to the extent of myocardial injury. Therefore, FluoroPharma believes that ischemic heart tissue can be reliably detected by using BFPET.

VasoPET: Vulnerable Plaque

FluoroPharma is developing VasoPET as a novel molecular imaging agent for the detection of vulnerable coronary artery plaque in patients with Coronary Artery Disease. The vulnerable (unstable) atherosclerotic plaque is recognized to be the primary culprit for the occurrence of myocardial and cerebral infarctions.

Rupture of such an atherosclerotic plaque triggers the formation of thrombi (blood clots) overlying the plaque, which frequently detach and occlude (clog) the vessels downstream, resulting in myocardial ischemia and/or myocardial infarction. In addition a ruptured plaque can “shed” cholesterol fragments “debris” from the plaque itself that also cause vessel occlusion as they move downstream. The risk for rupture and subsequent clinical consequences (such as a heart attack) is currently thought to correlate more with the presence of inflammation in the plaque than plaque size and arterial narrowing.

The detection of vulnerable plaque in atherosclerotic lesions is a desirable goal and to date remains both a significant unmet clinical objective and a substantial market opportunity.

VasoPET, if approved, may represent the first PET agent to image inflamed vascular plaque and could potentially differentiate between vulnerable and stable coronary artery plaque.

VasoPET has completed preclinical testing and preparation for an investigational new drug (IND) application is underway.

FluoroPharma’s portfolio also includes diagnostics for the early detection of Alzheimer’s disease.

AZPET: Early detection of Alzheimer’s disease

FluoroPharma’s early stage AZPET agents include an approach for directly imaging beta-amyloid plaque and the compensatory receptor systems in the elderly. Alzheimer’s disease patients may benefit from new treatments that have the potential to slow down disease progression and impact the healthcare costs associated with Alzheimer’s disease. Imaging and follow up with drugs like AZPET could allow these patients to receive the proper treatment earlier.

INTELLECTUAL PROPERTY

FluoroPharma obtained the licenses to the patents (composition of matter and some method of use patents) of the proprietary technology and indications related to their products from the Massachusetts General Hospital (MGH).

There are currently four patents issued and seven patent applications pending. Any future patent applications are expected to be initiated by FluoroPharma.

SUMMARY

“I have recently attended the Annual Meeting for the Society of Nuclear Medicine and Molecular Imaging, and I am encouraged and confident that FluoroPharma’s pipeline of innovative products is in alignment with the Society’s direction of developing novel imaging strategies, applicable to the era of molecular and personalized medicine. Scientific presentations and education sessions provided further support for advances in cardiac PET imaging and as presented in the meeting highlights lecture, more than 50% of the cardiology abstracts incorporated PET as a platform,” noted Mr. Spoor.

“The future for diagnostic imaging procedures with higher sensitivity and specificity is promising as they provide early and more accurate information to enable more effective treatment and follow-up of its efficacy. Early treatment means saving the patient from long and expensive hospital stays, which results in less time away from family and work.”

“Our future is defined by the potential of the market, and that too is strong. A high growth market provides burgeoning opportunities and we will be well positioned to seize those opportunities,” notes Mr. Spoor.

“As personalized medicine evolves, patients will see medical diagnostic products matched closely to therapeutics, such that they are more likely to be prescribed the exact treatment for their condition,” states Mr. Spoor. “This will improve chances for cure and reduce unnecessary costs and side effects.”

“And as we look forward to advances in science and medicine, FluoroPharma’s goal is to enable personalized medicine by enabling the physician to prescribe the right medicine, for the right person, at the right time for the right outcome. This is only possible with the right diagnostics.”

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma’s research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma’s filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.

The Company’s goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

The Company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer’s disease and agents that could potentially be used for imaging specific cancers.

In addition to the United States, Europe and China, patents related to FluoroPharma’s portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico. For more information on the Company, please visit: www.fluoropharma.com

CONTACT: Carol J. Perlman
         cperlman@fluoropharma.com
         917-592-9260
Monday, June 18th, 2012 Uncategorized Comments Off on FluoroPharma (FPMI) CEO Provides Shareholders With a “State of the Union” Communication

RadNet, Inc. (RDNT) to Present at the Wells Fargo Securities 2012 Healthcare Conference

LOS ANGELES, June 15, 2012 (GLOBE NEWSWIRE) — RadNet, Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Wells Fargo Securities 2012 Healthcare Conference in Boston, MA on Tuesday, June 19, 2012 at 01:30 p.m. Eastern Time.

There will be simultaneous and archived webcasts available at http://cc.talkpoint.com/well001/061912a_hr/?entity=60_5150UVD and www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website.

Details for RadNet’s Presentation:

Date: Tuesday, June 19, 2012
Time: 01:30 p.m. Eastern Time
Location: Intercontinental Hotel, Boston, MA

About RadNet, Inc.

RadNet, Inc. is a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 232 fully-owned and operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, Rhode Island, New Jersey and New York. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 6,300 employees. For more information, visit http://www.radnet.com.

The RadNet, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7212

CONTACT: RadNet, Inc.
         Mark Stolper
         Executive Vice President and Chief Financial Officer
         310-445-2800
Friday, June 15th, 2012 Uncategorized Comments Off on RadNet, Inc. (RDNT) to Present at the Wells Fargo Securities 2012 Healthcare Conference

DARA BioSciences (DARA) to Present Company Update at 2012 BIO Convention

DARA BioSciences, Inc. (Nasdaq: DARA) announced today that Dr. David J. Drutz, Chief Executive Officer, will provide a comprehensive update on the company’s products and pipeline at the 2012 BIO International Convention in Boston later this month. DARA’s presentation is part of the BIO Business Forum and is scheduled for 3:45 p.m. ET on Wednesday, June 20, Red Sox Room at the Boston Convention and Exhibition Center. DARA BioSciences focuses on oncology treatment and supportive care products.

Dr. Drutz will discuss the development and commercialization of DARA’s product portfolio, which includes Bionect®,a topical treatment for skin irritation and burns associated with radiation therapy, introduced to the market June 6, 2012; Soltamox®, the first and only oral liquid formulation of tamoxifen, widely used in the treatment and prevention of breast cancer, on track for launch in 2012; and KRN5500, under development for the treatment of neuropathic pain in patients with cancer, a condition with no current adequate therapy.

Attendees will be able to arrange one-on-one meetings with DARA in advance through the conference website 2012 BIO International Convention at http://convention.bio.org/.

The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO) and is the preeminent biotechnology meeting worldwide. Presenters at the BIO Business Forum will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture.

About DARA BioSciences, Inc.

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA sharpened its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox®. Soltamox® is a novel oral liquid formulation of tamoxifen, a product used widely in the treatment and prevention of breast cancer. Soltamox® is the only FDA approved oral liquid version of tamoxifen and fulfills a vital clinical need for patients who cannot tolerate existing tablet formulations of this drug. DARA plans to begin marketing Soltamox® in the U.S. in the third quarter of 2012.

DARA has also obtained exclusive U.S. commercial rights from Innocutis Holdings, LLC for Bionect® (hyaluronic acid sodium salt, 0.2%) within the oncology and radiation oncology marketplace. Bionect is an FDA-cleared product indicated for the management of irritation of the skin as well as first and second degree burns. Bionectis currently being promoted and sold by Innocutis in the dermatology market. DARA launched this product in Q2 2012.

DARA has obtained, in addition, the U.S. rights to gemcitabine, a widely used generic chemotherapeutic cancer drug, from Uman Pharma. The Abbreviated New Drug Application (ANDA) for gemcitabine is expected to be filed with the FDA later this year.

DARA is also developing KRN5500 for the treatment of neuropathic pain in patients with cancer. KRN5500 has successfully completed a Phase 2a study and has been designated as a Fast Track Drug by the FDA. DARA is working with the National Cancer Institute (NCI) to design an additional clinical trial under joint DARA-NCI auspices while considering further internal Phase 2 development.

In addition, DARA’s pipeline includes DB959, a novel, non-TZD dual delta/gamma PPAR agonist for the treatment of type 2 diabetes and dyslipidemia. DARA has completed Phase 1 testing of DB959 and is presently pursuing opportunities to out-license this product. DARA also has rights to other PPAR and DPPIV-inhibitor compounds for which it intends to seek out-licensing or partnering opportunities.

For more information please visit our web site at http://www.darabio.com.

Safe Harbor Statement

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to DARA’s ability to timely commercialize and generate revenues or profits from Bionect®, Soltamox® or other products given that DARA only recently hired its initial sales force and DARA’s lack of history as a revenue-generating company, FDA and other regulatory risks relating to DARA’s ability to market Bionect, Soltamox or other products in the U.S. or elsewhere, DARA’s ability to develop and bring new products to market as anticipated, DARA’s current cash position and its need to raise additional capital in order to be able to continue to fund its operations, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA’s intellectual property and the intellectual property of others, the potential delisting of DARA’s common stock from the NASDAQ Capital Market, risks and uncertainties relating to DARA’s ability to successfully integrate Oncogenerix and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission (“SEC”). Copies of DARA’s filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA’s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.

Friday, June 15th, 2012 Uncategorized Comments Off on DARA BioSciences (DARA) to Present Company Update at 2012 BIO Convention

THQ (THQI) Announces Start of Darksiders® II Summer of Death Promotion

THQ Inc. (NASDAQ: THQI) today announced that Darksiders® II US community members will be given the chance to earn exclusive rewards during the Summer of Death Promotion.

To kick off the promotion any fan who pre-orders a copy of Darksiders II on the Xbox 360® videogame and entertainment system from Microsoft, Playstation®3 or Windows PC will be eligible to receive an exclusive t-shirt once the game releases. To receive their shirt, individuals who pre-order Darksiders II will need to retain their original pre-order receipt, pay for shipping and handling and follow the instructions for t-shirt redemption on the Darksiders II Facebook page.

Additional rewards will be made available throughout the Summer of Death including digital content and ‘money can’t buy prizes’. To keep up to date on the Summer of Death and all other promotions follow Darksiders II at Facebook.com/Darksiders.

Jim Huntley, Vice President of Global Brand Marketing commented: “The Summer of Death is an exciting campaign of promotions and giveaways intended to reward our most loyal fans.”

Darksiders II follows the exploits of DEATH, one of the four horsemen of the Apocalypse, in an action-packed tale that runs parallel to the events in the original Darksiders game. This epic journey propels DEATH through various light and dark realms as he tries to redeem his brother WAR, the horseman blamed for prematurely starting the Apocalypse in Darksiders.

Darksiders II is scheduled to be available for console and PC in August 2012, for more information check www.Darksiders.com .

About Darksiders 2

Awakened by the End of Days, DEATH, the most feared of the legendary Four Horsemen embarks on a quest to redeem his brother’s name. Become the terrifying force which everything fears but nothing can escape.

The original Darksiders®, released in January 2010, received critical acclaim including the Best Fantasy Game 2010 award from IGN. Darksiders followed the story of WAR, wrongly accused of starting the apocalypse, on a quest to reclaim lost honor and take revenge on those who wronged him.

About THQ

THQ Inc. (NASDAQ: THQI) is a leading worldwide developer and publisher of interactive entertainment software. The company develops its products for all popular game systems, personal computers and wireless devices. Headquartered in Los Angeles County, California, THQ sells product through its global network of offices located throughout North America, Europe and Asia Pacific. More information about THQ and its products may be found at www.thq.com. THQ, Darksiders and their respective logos are trademarks and/or registered trademarks of THQ Inc.

Microsoft, Xbox, Xbox 360, Xbox LIVE, the Xbox logos, and the Xbox LIVE logo are either registered trademarks or trademarks of Microsoft Corporation in the U.S. and/or other countries.

“PlayStation” is a registered trademark of Sony Computer Entertainment Inc.

All other trademarks are the property of their respective owners.

The statements contained in this press release that are not historical facts may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the business of THQ Inc. and its subsidiaries (collectively referred to as “THQ”), including, but not limited to, expectations and projections related to the Darksiders II video game and are based upon management’s current beliefs and certain assumptions made by management. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, business, competitive, economic, legal, political and technological factors affecting our industry, operations, markets, products or pricing. Readers should carefully review the risk factors and the information that could materially affect THQ’s financial results, described in other documents that THQ files from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal period ended March 31, 2012 and subsequent Quarterly Reports on Form 10-Q, and particularly the discussion of trends and risk factors set forth therein. Unless otherwise required by law, THQ disclaims any obligation to update its view on any such risks or uncertainties or to revise or publicly release the results of any revision to these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Friday, June 15th, 2012 Uncategorized Comments Off on THQ (THQI) Announces Start of Darksiders® II Summer of Death Promotion

Idera Pharmaceuticals (IDRA) to Present at the 2012 BIO International Convention

Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing novel therapeutics for autoimmune diseases and vaccine adjuvants, today announced that members of the management team will be presenting at the 2012 BIO International Convention at the Boston Convention and Exhibition Center in Boston, MA. The presentation will be made during the BIO Business forum EST in the Celtics Room (104C) on Wednesday, on June 20th, 2012 at 10:30am.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has clinical development programs in autoimmune diseases and cancer. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants. The Company is also advancing its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.

Friday, June 15th, 2012 Uncategorized Comments Off on Idera Pharmaceuticals (IDRA) to Present at the 2012 BIO International Convention

Zynga (ZNGA) Rolls Out Zynga Slots, a New Mobile Game for iPhone, iPad and iPod

New Slots Game Expands Successful Zynga Casino Mobile Franchise

SAN FRANCISCO, June 15, 2012 (GLOBE NEWSWIRE) — Zynga (Nasdaq:ZNGA), the world’s leading provider of social game services, today announced the global launch of Zynga Slots, a mobile slots experience for iPhone, iPad and iPod touch that brings a fresh spin to the casino genre. Zynga Slots is the second mobile title in the popular Zynga Casino category, and the third game in the franchise which also includes Zynga Poker and Zynga Bingo.

Developed by the same team that created the wildly popular mobile Zynga Poker game, Zynga Slots ups the ante in the mobile casino experience with innovative features including seamless game play, high-quality graphics and never-before-seen social elements to deliver the ultimate slots experience for casino fans and new players alike. Launching today on the App Store, Zynga Slots reinforces Zynga’s dedication to delivering free, social and high-quality mobile games across multiple platforms.

“As Zynga’s second mobile casino game, Zynga Slots brings the thrill of Las Vegas slot machines to the palm of players’ hands while introducing social elements for players to share the excitement with their friends,” said Justin Cinicolo, vice president, Zynga Mobile. “We’re continually listening to player feedback on the kinds of games they enjoy playing, and we’ll be sure to bring more high-quality iOS games to players based on the genres they enjoy.”

Zynga Slots players can enjoy a host of new features to spin and win like never before.

  • We Upped The Ante: Never miss a jackpot. Zynga introduces offline mode, which enables players to enjoy Zynga Slots anywhere, anytime. With minimal load times and smooth reel animations, Zynga Slots offers an unparalleled player experience.
  • Hit the Jackpot: Zynga Slots is the most social slots game to date – meaning more friends and more winnings. Recruit friends to play and watch as the jackpot rises before your eyes. Or, hop on a machine to help heat it up and reap the rewards for your good deed. With seamless Facebook integration and push notifications, you will always know when the jackpot increases or a friend wins big—and when it is time to spin again.
  • Master Machines and Move On Up: As you master slot play, you will level-up to unlock rewards such as new machines featuring themes from some popular Zynga games including FarmVille and Hanging With Friends. Dedicated players will also reap the benefits of increased pay lines and higher betting limits for bigger risk and better rewards.
  • Spin for a Surprise: Zynga Slots goes beyond basic slot gameplay with new features like delightful animations, mini-games and fun character touches. Playful characters react and move with each spin, inching players closer to “Fever Mode,” a 30-second bonus round where you’ll spin as much as you can for an even bigger payout!
  • Spin, Girar, Tourner: Lost in translation? Not in this game. Zynga Slots is available in 10 languages, so you can spin, bet and win no matter what language you speak. ¿Cómo se dice jackpot?

The Casino genre is a popular form of entertainment around the world, and Zynga Slots is designed with a global audience in mind. The game is launching in 10 languages: English, French, Italian, German, Spanish, Portuguese, Traditional Chinese, Simplified Chinese, Japanese and Korean.

Zynga’s iOS portfolio continues to grow and Zynga Slots is launching on the heels of recently launched Matching With Friends, Zombie Swipeout and Scramble With Friends.

Zynga Slots is available for free from the App Store on iPhone, iPad and iPod touch or at www.itunes.com/appstore.

Game logo and images can be found here: https://zynga.box.com/s/08efb11f9c0f19c6b368

About Zynga Inc.

Zynga Inc. (Nasdaq:ZNGA) is the world’s leading provider of social game services with more than 290 million monthly active users playing its games, which include CityVilleFarmVilleWords With FriendsScramble With FriendsCastleVilleHidden ChroniclesZynga PokerEmpires & AlliesIndiana Jones™ Adventure WorldThe Pioneer TrailMafia Wars and Café World. Zynga’s games are available on a number of global platforms, including Facebook, Zynga.com, Google+, Tencent, Apple iOS and Google Android. Through Zynga.org, Zynga players have raised more than $10 million for world social causes. Zynga is headquartered in San Francisco, Calif.

The Zynga Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11743

CONTACT: Morgan Mathis
         press@zynga.com
Friday, June 15th, 2012 Uncategorized Comments Off on Zynga (ZNGA) Rolls Out Zynga Slots, a New Mobile Game for iPhone, iPad and iPod

Hoku’s (HOKU) Board of Directors Forms Restructuring Committee

HONOLULU, HI — (Marketwire) — 06/15/12 — Hoku Corporation (NASDAQ: HOKU), a solar energy products and services company, today announced that its board of directors has formed a five-member committee to oversee and direct the Company’s efforts to restructure its liabilities. Scott Paul, an executive officer of Hoku Corporation since 2003, and the Company’s chief executive officer since 2010, will resign as CEO on June 30, and continue as a director and chairman of the newly formed restructuring committee. “Jeremy” Xiaoming Yin, the Company’s president since early 2011, will begin reporting directly to the board of directors as the acting chief executive officer.

“One purpose of the restructuring committee is to ensure independent oversight of the restructuring process,” said Scott Paul. “In order to dedicate the proper focus and attention to this responsibility, I have decided to step down as CEO. I have the utmost confidence in Jeremy’s ability to lead Hoku.”

Hoku Corporation also announced that it is exploring opportunities to sell Hoku Solar, the Company’s wholly owned subsidiary that markets and installs turnkey photovoltaic systems and provides related services in Hawaii.

“While we explore this opportunity, Hoku Solar will continue normal operations as a provider of investment-grade PV in Hawaii,” said Paul. “Under the continuing leadership of Jerrod Schreck, Hoku Solar remains focused on developing and delivering value-engineered, top-performing solar energy facilities for its commercial, institutional and utility clients. Hoku Solar is actively building several of the largest utility-scale photovoltaic projects in the State of Hawaii, and we believe there is substantial value that could be realized for the benefit of Hoku Corporation’s stakeholders.”

About Hoku Corporation
Hoku Corporation (NASDAQ: HOKU) is a solar energy products and services company with two business units: Hoku Materials and Hoku Solar. For more information, visit www.hokucorp.com. Hoku, Hoku Solar, and the Hoku Corporation logo are trademarks of Hoku Corporation, and Hoku Materials is the trademark of Hoku Materials, Inc., all rights reserved. All other trademarks, trade names and service marks appearing in this press release are the property of their respective holders. ©Copyright 2012, Hoku Corporation, all rights reserved.

Forward-Looking Statements
This press release contains forward-looking statements that involve many risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, the Company’s ability to restructure its liabilities and the liabilities of Hoku Materials, the possible sale of Hoku Solar, Hoku Solar’s ability to continue its business operations, and the risks, uncertainties and other factors disclosed in the Company’s most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. In evaluating these statements, you should specifically consider the risks described in the Company’s filings with the Securities and Exchange Commission, as applicable. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Monica Salter
Bennet Group
Tel: 808-265-0073
Email: Email Contact

Investor Relations Inquiries:
Hoku Corporation
Tel: 808-682-7800

Friday, June 15th, 2012 Uncategorized Comments Off on Hoku’s (HOKU) Board of Directors Forms Restructuring Committee

FluoroPharma Medical, Inc. (FPMI) Appoints Thijs Spoor Chairman of the Board

MONTCLAIR, N.J., June 15, 2012 (GLOBE NEWSWIRE) — FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, is pleased to announce the appointment of Thijs Spoor, to the position of Chairman of the Board. Mr. Spoor will assume the role formerly held by Dr. David Elmaleh, who has left the company. Mr. Spoor will also continue as President and CEO.

Mr. Spoor was appointed President and CEO of FluoroPharma Inc. on September 15, 2010. He was previously CFO for Sunstone BioSciences. Prior to joining Sunstone BioSciences, he worked as a consultant at Oliver Wyman, focusing on pharmaceutical and medical device companies. Mr. Spoor has also been an equity research analyst at J.P. Morgan and Credit Suisse, covering the Biotechnology and Medical Device industries. Mr. Spoor worked in the pharmaceutical industry, spending 10 years with Amersham / GE Healthcare where he oversaw the nuclear cardiology portfolio and most recently as the Director of New Product Opportunities leading the PET strategic plan.

Mr. Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.

The Company’s goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

The Company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer’s disease and agents that could potentially be used for imaging specific cancers.

In addition to the United States, Europe and China, patents related to FluoroPharma’s portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico. For more information on the Company, please visit: www.fluoropharma.com

CONTACT: Carol J. Perlman
         cperlman@fluoropharma.com
         917-592-9260
Friday, June 15th, 2012 Uncategorized Comments Off on FluoroPharma Medical, Inc. (FPMI) Appoints Thijs Spoor Chairman of the Board

Dehaier Medical (DHRM) Develops New Proprietary High-Efficiency Oxygen Inhaler

BEIJING, June 14, 2012 /PRNewswire-Asia-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: DHRM) (“Dehaier” or the “Company”), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has co-developed its “High-Efficiency Oxygen Inhaler” with Dr. Ding Jianzhang of Beijing Haidian Hospital, which is expected to begin selling in the third quarter of 2012 in mainland China. The portable device is designed for use in homecare oxygen therapy, emergency treatment, disaster relief activities and high-altitude settings.

(Photo: http://photos.prnewswire.com/prnh/20120614/CN24727 )
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )

Dr. Ding Jianzhang, the author of “Oxygen Therapeutics & Health”, has over 30 years experience, specializing in hyperbaric oxygen treatment. In 2003, he received a patent for an atmospheric oxygen therapy mask. Dehaier obtained an exclusive license to Dr. Ding’s patent and has re-designed, developed and used this patent to create the High-Efficiency Oxygen Inhaler. The Inhaler is easily portable and features instantaneous high volume oxygen delivery, while also reducing waste through its uniquely triggered oxygen conveying system. The system supplies oxygen volume automatically according to patient lung capacity and delivers oxygen only on inhalation. The Company is going to apply a patent on its design and technology of this newly-developed High-Efficiency Oxygen Inhaler from the China Patent and Trademark office.

Dehaier Medical’s CEO, Mr. Ping Chen commented, “We continue to devote our research and development efforts toward markets where we feel there is a distinct need. After a thorough review, we felt that a portable and efficient solution for individuals with severe oxygenation failure or cerebrovascular disease (blood circulation to the brain) would improve their standard of living and fill a distinct niche in China’s medical homecare market. In addition, we expect that our new inhaler will be attractive to athletes such as mountain climbers, emergency rescue personnel and others who need portable and convenient oxygen solutions. We are proud to provide the state of art High-Efficiency Oxygen Inhaler to the market, which again represents our business growth strategy of diversifying sales through shifting focus to homecare medical segment and enriching the product line of home oxygen therapy services. We look forward to realizing considerable sales from the product in near future.”

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier’s technology is based on six patents and five software copyrights; additionally Dehaier has two pending software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn.

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular statements about Dehaier’s newly developed High-Efficiency Oxygen Inhaler. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Us

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn

Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn

The Equity Group Inc.
Katherine Yao
+86 10-6587-6435
kyao@equityny.com

In America

The Equity Group Inc.
Adam Prior
(212) 836-9606
aprior@equityny.com

Thursday, June 14th, 2012 Uncategorized Comments Off on Dehaier Medical (DHRM) Develops New Proprietary High-Efficiency Oxygen Inhaler

Tegal Corp. (TGAL) Reports Fiscal Year 2012 Financial Results

Tegal Corporation (NASDAQ:TGAL) today announced financial results for the Fourth Quarter and Fiscal Year 2012, which ended March 31, 2012.

Fiscal 2012 Fourth Quarter Financial Statement Highlights

  • The Company’s Net (Loss) per share in the Fourth Quarter of Fiscal Year 2012 was ($1.32), compared with ($0.42) in the Fourth Quarter of the prior fiscal year and $1.34 in the Third Quarter of Fiscal Year 2012.
  • Tegal recorded a Net Loss of ($2,227) in the Fourth Quarter of Fiscal Year 2012. The Company wrote off the investment in Sequel Power and recognized its proportionate share of Sequel Power’s operating loss of ($1,545) in the Fourth Quarter of Fiscal Year 2012.
  • Tegal ended the Fourth Quarter of Fiscal Year 2012 with approximately $7.8 million in cash.

Fiscal 2012 Financial Statement Highlights

  • The Company’s Net (Loss) per share decreased to ($0.85) for the year from a comparable ($1.85) from the prior fiscal year.
  • The Company ended the fiscal year with $7.8 million in cash, an increase over the prior year of approximately $0.2 million. This balance reflects the use of cash for the investment in NanoVibronix and proceeds of the IP asset sale.

Fiscal 2012 Business Highlights

Tegal and its portfolio companies achieved numerous milestones in Fiscal Year 2012. Tegal’s two portfolio companies are Sequel Power, a private company dedicated to the development and operation of large scale photovoltaic (PV)-based solar utility projects, and NanoVibronix Inc., a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology.

Among the highlight’s of Fiscal 2012:

  • Tegal awarded patents to multiple bidders for three of the four bid lots of Tegal’s NLD Patent Portfolio recently offered for sale for an aggregate consideration of approximately $4 million. Tegal received approximately $3.8 million in the Fiscal Year 2012. Tegal sold over 30 patents from the NLD portfolio—which includes more than 35 U.S. and international patents in the areas of pulsed-chemical vapor deposition (CVD), plasma-enhanced atomic-layer deposition (ALD) and NLD. NLD is a process technology that bridges the gap between high throughput, non-conformal chemical vapor deposition and lower throughput, highly conformal atomic layer deposition (ALD). Tegal offered the patent portfolio for sale earlier in 2011 in an effort to complete the divestment of its semiconductor capital equipment assets. Tegal also reported ongoing discussions regarding placement of Lot 4 of the NLD Patent portfolio, which applies to copper barrier and low-k dielectric technology. Interest in Lot 4 is coming primarily from IC device manufacturers, the company said.
  • Tegal made a $300,000 strategic investment in NanoVibronix Inc., a medical device company focused on creating products utilizing its proprietary low-intensity surface acoustic wave (SAW) technology. The company’s unique, patented approach enables the transmission of low-frequency, low-intensity ultrasound waves through a variety of soft, flexible materials, including skin and tissue, enabling low-cost, breakthrough devices targeted at large, high-growth markets.
  • Sequel Power opened offices in Buenos Aires, Argentina, and Santiago, Chile, during the Fourth Quarter. The offices serve Sequel Power’s customers and partners in South America and are overseen by Prince Alexander von Sachsen, Sequel Power’s Chairman of South America and Middle East/Africa. Sequel Power is currently working on South American large-scale photovoltaic-based solar utilities projects in California, Chile and Ecuador.

“Tegal emerges from Fiscal 2012 with a substantially strengthened balance sheet and excellent prospects for additionally monetizing our IP portfolio,” said Thomas Mika, President and Chief Executive Officer of Tegal. “Our investment focus became more tightly focused on healthcare technologies, whose growth is driven by government mandates and increasing demands for efficiency. We expect healthcare technology to be a significant part of our growth in Fiscal 2013.”

Safe Harbor Statement

Except for historical information, matters discussed in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “project” or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to industry conditions, economic conditions, acceptance of new technologies, market acceptance of the Company’s products and services, the Company’s exploration and execution of strategic alternatives. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. For a further discussion of these risks and uncertainties, please refer to the Company’s periodic filings with the Securities and Exchange Commission.

About Tegal

Since its founding in 1972, Tegal Corporation has been dedicated to the development and application of emerging technologies. Often on the forefront of major inventions, Tegal’s process and capital equipment know-how enabled the development and manufacturing of leading-edge devices – from early microprocessors to advanced memory and LEDs, as well as to newest filtering and sensing devices that are present in the most advanced smart phones. Tegal draws upon its historic market and technology leadership in semiconductors and MEMS devices to engage in the promotion of other emerging technologies, including PV-based solar power generation and medical diagnostic and therapeutic devices. Tegal is actively evaluating opportunities for partnerships with diversified technology-based companies in order to exploit our shared experience and to enhance our value as a public company. Tegal is headquartered in Petaluma, California. Please visit us on the web at www.tegal.com.

TEGAL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

ASSETS
March 31,
2012
March 31,
2011
Current assets:
Cash and cash equivalents $ 7,820 $ 7,575
Restricted Cash 200
Prepaid expenses and other current assets 56 139
Other assets of discontinued operations 418 1,129
Total current assets 8,294 9,043
Property and equipment, net 56 112
Investment in unconsolidated affiliate 2,046
Investment in convertible promissory note 312
Total assets $ 8,662 $ 11,201
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 1 $ 262
Common Stock Warrant Liability 19 26
Accrued expenses and other current liabilities 316 94
Liabilities on discontinued operations 246 1,410
Total liabilities 582 1,792
Stockholders’ equity:
Common stock 17 17
Additional paid-in capital 129,052 128,977
Accumulated other comprehensive income (142) (167)
Accumulated deficit (120,847) (119,418)
Total stockholders’ equity 8,080 9,409
$ 8,662 $ 11,201
TEGAL CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Year Ended

March 31,

2012 2011
Revenue – related party $ 100 $ 16
Operating expenses:
General and administrative expenses 2,615 1,883
Total operating expenses 2,615 1,883
Operating loss (2,515) (1,867)
Equity in (loss) and impairment of unconsolidated affiliate (2,046) (179)
Other income (expense), net 18 337
Loss before income tax benefit (4,543) (1,709)
Income tax expense (benefit) expense
Loss from continuing operations (4,543) (1,709)
Gain on sale of discontinued operations, net of tax 2,930 506
Income (loss) from discontinued operations, net of taxes 184 (1,927)
Income (loss) from discontinued operations 3,114 (1,421)
Net loss $ (1,429) $ (3,130)
Other comprehensive income (loss) 25 (18)
Total comprehensive (loss) $ (1,404) $ (3,148)
Net (loss) income per share from continuing operations:
Basic and diluted $ (2.69) $ (1.01)
Net (loss) income per share from discontinued operations:
Basic and diluted $ 1.84 $ (0.84)
Net (loss) income per share:
Basic and diluted $ (0.85) $ (1.85)
Weighted average shares used in per share computation:
Basic and diluted 1,689 1,689
Thursday, June 14th, 2012 Uncategorized Comments Off on Tegal Corp. (TGAL) Reports Fiscal Year 2012 Financial Results

JA Solar (JASO) Announces Share Repurchase Program

SHANGHAI, China, June 14, 2012 (GLOBE NEWSWIRE) — JA Solar Holdings Co., Ltd. (Nasdaq:JASO) (“JA Solar” or the “Company”), one of the world’s largest manufacturers of high-performance solar power products, today announced that its board of directors has approved a share repurchase program, effective immediately, that authorizes JA Solar to repurchase up to a US$100 million worth of its issued and outstanding American Depositary Shares (“ADSs”) prior to September 30, 2012.

The program permits the Company to purchase ADSs from time to time prior to September 30, 2012 on the open market at prevailing market prices, in accordance with applicable securities laws and subject to restrictions relating to volume, price and timing.

About JA Solar Holdings Co., Ltd.

JA Solar Holdings Co., Ltd. is a leading manufacturer of high-performance solar power products that convert sunlight into electricity for residential, commercial, and utility-scale power generation. The Company is one of the world’s largest producers of solar cells. Its standard and high-efficiency product offerings are among the most powerful and cost-effective in the industry. The Company also produces solar modules that it distributes under its own brand and produces on behalf of solar manufacturers globally. The Company shipped 1.69 GW of solar power products in 2011. JA Solar is headquartered in Shanghai, China, and maintains production facilities in Shanghai, as well as Hebei, Jiangsu and Anhui provinces. For more information, please visit www.jasolar.com.

The JA Solar Holdings Co., Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8631

Forward-looking Statements

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words such as “may,” “expect,” “anticipate,” “aim,” “intend,” “plan,” “believe,” “estimate,” “potential,” “continue,” and other similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. Further information regarding these and other risks is included in Form 20-F and other documents filed with or furnished to the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

CONTACT: In China

         Martin Reidy
         Brunswick Group
         Tel: +86-10-5960-8600
         E-mail:jasolar@brunswickgroup.com

         In the U.S.

         Cindy Zheng
         Brunswick Group
         Tel: +1-212-333-3810
         E-mail:jasolar@brunswickgroup.com
Thursday, June 14th, 2012 Uncategorized Comments Off on JA Solar (JASO) Announces Share Repurchase Program

General Moly (GMO) Announces Mt. Hope Water Rights Approval

General Moly, Inc. (the “Company”) (NYSE MKT and TSX: GMO) today, announced that a Nevada State District Court (“the Court”) issued its Order affirming the Nevada State Engineer’s (“the NSE”) Ruling of July 2011 approving the Mt. Hope Project’s water rights and the NSE’s December 2011 and January 2012 issuance of water permits for the Mt. Hope Project.

The 59 page Order, which has been posted to the Press Release section of the Company’s website, describes the Petitioners’ arguments before the Court and denies all Petitioners’ respective petitions for Judicial Review.

Bruce D. Hansen, Chief Executive Officer of General Moly, said, “I am extremely pleased that the State Engineer’s thorough and inclusive process in approving the Mt. Hope Project’s water rights and permits has been affirmed by the Court. Obtaining water rights for the Mt. Hope Project has been a long process and I am eager to move beyond the protests and appeals of the past three years toward a more positive and engaged dialogue with the County of Eureka and its citizens. The 3M Plan, approved by the NSE earlier this week, provides mitigation protections to other water users if impacts are caused by the Mt. Hope project. With full access to our water rights and permits we look forward to the receipt of our remaining State and Federal permits and initiating construction activities later this year. The Mt. Hope project is moving forward.”

General Moly is a U.S.-based molybdenum mineral development, exploration and mining company listed on the NYSE MKT (formerly the NYSE AMEX) and the Toronto Stock Exchange under the symbol GMO. Our primary asset, our interest in the Mt. Hope project located in central Nevada, is considered one of the world’s largest and highest grade molybdenum deposits. Combined with our second molybdenum property, the Liberty project that is also located in central Nevada, our goal is to become the largest primary molybdenum producer by the middle of the decade. For more information on the Company, please visit our website at http://www.generalmoly.com.

Forward-Looking Statements

Statements herein that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act, as amended and Section 21E of the Securities Exchange Act of 1934, as amended and are intended to be covered by the safe harbor created by such sections. Such forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, expected, or implied by the Company. These risks and uncertainties include, but are not limited to, metals price and production volatility, global economic conditions, currency fluctuations, increased production costs and variances in ore grade or recovery rates from those assumed in mining plans, exploration risks and results, political, operational and project development risks, including the Company’s ability to obtain required permits to commence production and its ability to raise required financing, adverse governmental regulation and judicial outcomes. The closing of the Hanlong transaction and obtaining bank financing are subject to a number of conditions precedent that may not be fulfilled. For a detailed discussion of risks and other factors that may impact these forward looking statements, please refer to the Risk Factors and other discussion contained in the Company’s quarterly and annual periodic reports on Forms 10-Q and 10-K, on file with the SEC. The Company undertakes no obligation to update forward-looking statements.

Thursday, June 14th, 2012 Uncategorized Comments Off on General Moly (GMO) Announces Mt. Hope Water Rights Approval

Champion (CHMP) Reports Results For 2nd Qtr. And Year To Date 2012

HUNTINGTON, W.Va., June 14, 2012 /PRNewswire/ — Champion Industries, Inc. (NASDAQ: CHMP) today announced a second quarter 2012 net loss of $(21.0) million or $(1.86) per share on a basic and diluted basis. This compares to net income of $493,000 or $0.05 per share on a basic and diluted basis for the three months ended April 30, 2011.

Net loss for the six months ended April 30, 2012 was $(21.1) million or $(1.87) per share on a basic and diluted basis. This compares with net income of $566,000 or $0.06 per share on a basic and diluted basis for the six months ended April 30, 2011.

The losses for the second quarter and six months ended April 30, 2012 were reflective of pre-tax non-cash charges of $9.5 million associated with impairment of goodwill at the newspaper segment and an increase in the deferred tax asset valuation allowance of $15.2 million.

Marshall T. Reynolds, Chairman of the Board and Chief Executive Officer of Champion, said, “Our second quarter and first six months of 2012 was negatively impacted due to two charges associated with certain non-cash events. When we step back and look at the fundamental operations of the Company we have grown sales for the year to date period to $65.0 million from $62.9 million in the previous year or 3.4% and when we look at the second quarter of 2012 compared to the prior year we have grown sales 7.7%. We have been able to continue to successfully operate our businesses while devoting substantial efforts, funds and resources to identify an appropriate deleveraging path with our secured lenders. As a result of these actions we incurred approximately $1.1 million in increased professional fees primarily associated with actions associated with our credit facilities.  The Company continues to work diligently to implement a restructuring plan submitted to our secured lenders and we believe certain facets of this plan will improve overall productivity and efficiency of the Company, which should result in enhanced results and benefit all interested parties. The key for us in 2012 will be to continue to focus on our cost structure while assuring we provide an adequate infrastructure to support our sales initiatives and address our secured lender initiatives. To accomplish this we must get better and more efficient in all components of our business.”

Revenues for the three months ended April 30, 2012 were $33.4 million compared to $31.0 million in the same period in 2011. This change represented an increase in revenues of $2.4 million or 7.7%. The printing segment experienced an increase of $1.2 million or 6.1% while the office products and office furniture segment experienced an increase of $1.2 million or 14.6%. The newspaper revenues for the quarter increased $16,000 when compared to the prior period. On a year to date basis for the six months ended April 30, 2012 revenues increased to $65.0 million from $62.9 million in the prior year or 3.4%. The printing segment experienced an increase of 3.0% from $39.2 million to $40.4 million. The office products and office furniture segment experienced an increase of 6.2% from $16.3 million to $17.3 million. The newspaper segment revenues decreased by less than 1% during this period and approximated $7.3 million for each period.

At April 30, 2012, the Company had approximately $46.1 million of interest bearing debt, of which $43.3 million is syndicated. The syndicated debt has been reduced by approximately $42.2 million since inception of the debt, which resulted primarily from the acquisition of The Herald-Dispatch in September 2007. This represents a reduction of over 49% in a period slightly more than 4.5 years. This debt was paid down during a significant economic downturn and severe secular decline within our printing and newspaper segments. The Company has achieved this debt reduction through a combination of earnings, cash flow, equity additions and working capital management. The Company is subject to certain restrictive financial covenants requiring the Company to maintain certain financial ratios. The Company was not in compliance with these covenants at October 31, 2011 and April 30, 2012 and therefore the Company is currently operating under a Notice of Default and Reservation of Rights Letter which essentially indicates that any additional credit extended to the Company would be made by the Lenders in their sole discretion without any intention to waive any Events of Default. The Company has continued to have availability of additional credit through its revolving line of credit during this default period.

Mr. Reynolds concluded, “We have much to achieve in 2012 and we refuse to take our eye off the ball in terms of our core business. We are cognizant that we must address our debt situation and our pending line of credit maturity but we ultimately believe striving to improve our core business is a fundamental component of a solution for all parties in this regard. We are also aware that we may need to continue the exploration of additional strategic initiatives including asset sales that make reasonable sense to all parties. We also must diligently strive to complete certain initiatives, which are currently in process, but not yet completed as these actions should assist in accomplishing our long term goals. The Company has many tasks to accomplish but we are committed to staying the course and persevering through the challenges ahead. ”

Champion is a commercial printer, business forms manufacturer and office products and office furniture supplier in regional markets east of the Mississippi. Champion also publishes The Herald-Dispatch daily newspaper in Huntington, WV with a total daily and Sunday circulation of approximately 24,000 and 30,000, respectively. Champion serves its customers through the following companies/divisions: Chapman Printing (West Virginia and Kentucky); Stationers, Champion Clarksburg, Capitol Business Interiors, Garrison Brewer, Carolina Cut Sheets, U.S. Tag and Champion Morgantown (West Virginia); Champion Output Solutions (West Virginia); The Merten Company (Ohio); Smith & Butterfield (Indiana and Kentucky); Champion Graphic Communications (Louisiana); and Consolidated Graphic Communications (Pennsylvania, New York and New Jersey); Donihe Graphics (Tennessee); Blue Ridge Printing (North Carolina) and Champion Publishing (West Virginia, Kentucky and Ohio).

Certain Statements contained in the release, including without limitation statements including the word “believes”, “anticipates,” “intends,” “expects” or words of similar import, constitute “forward-looking statements” within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such factors include, among others, general economic and business conditions, changes in business strategy or development plans and other factors referenced in this release. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

Champion Industries, Inc. and Subsidiaries

Summary Financial Information (Unaudited)

Three Months ended April 30,

Six Months ended April 30,

2012

2011

2012

2011

Total Revenues

$    33,389,000

$    31,013,000

$    64,990,000

$    62,855,000

Net (loss) income

$  (21,016,000)

$         493,000

$  (21,102,000)

$         566,000

Per share data:

Net (loss) income

Basic and diluted

$             (1.86)

$               0.05

$             (1.87)

$               0.06

Weighted Average  Shares outstanding:

Basic

11,300,000

9,988,000

11,300,000

9,988,000

Diluted

11,300,000

9,988,000

11,300,000

9,988,000

The following table is a reconciliation of net (loss) income as reported to core net income, which is defined as GAAP net (loss) income adjusted for restructuring and other charges, changes in the valuation allowance of deferred tax assets and goodwill impairment charges. The Company believes that these items require additional disclosure and therefore, the Company has disclosed additional non-GAAP financial measures in an effort to make the quarterly and six months financial statements more useful to investors. The Company has not disclosed the advisory fees and other debt related fees in this schedule.

Three Months ended April 30,

Six Months ended April 30,

2012

2011

2012

2011

Net (loss) income

$  (21,016,000)

$         493,000

$  (21,102,000)

$         566,000

Restructuring and other, Net of tax

150,000

Goodwill Impairment, Net of tax

6,039,000

6,039,000

Increase in Valuation allowance of
Deferred Tax Assets

15,209,000

15,209,000

Core Net Income

$         232,000

$         493,000

$         146,000

$         716,000

Thursday, June 14th, 2012 Uncategorized Comments Off on Champion (CHMP) Reports Results For 2nd Qtr. And Year To Date 2012

Simulations Plus (SLP) Signs Collaboration Agreement

Major Pharmaceutical Company to Fund Enhanced Oral Cavity Model in GastroPlus™

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced today that it has signed a collaboration agreement with a top-5 pharmaceutical company to extend and enhance its oral cavity dosing model within its industry gold standard GastroPlus™ simulation software program.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “We’re very pleased to announce this collaboration, which will extend and enhance the GastroPlus simulation model for drug dosing in the oral cavity, such as sublingual, lingual and buccal (inside the cheek) dosing through a variety of dosage forms. These agreements will continue to extend the competitive advantage of our GastroPlus program, adding industry leading capabilities without the need for Simulations Plus to fund the development directly. These will include rapid-dissolving tablets, solutions, suspensions, oral sprays, and buccal patches. When it is appropriate for a particular drug, oral cavity dosing can have significant advantages over traditional swallowed oral doses, including more rapid absorption and onset of action, and reduced loss of drug due to first-pass metabolism in the liver.”

John DiBella, vice president of marketing and sales for Simulations Plus, added: “This is our first new funded collaboration since we completed several others two years ago. The funding support we will receive will add to our steady growth in software licensing revenues, which has had to make up for the lack of collaboration funding in recent quarters when compared to their year-previous quarters, as well as adding to the revenue growth we’ve experienced. We are currently in final negotiations with another top pharmaceutical company for yet another funded collaboration intended to enhance GastroPlus, and we expect to announce it in the very near future.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com.

Follow Us on Twitter

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

Wednesday, June 13th, 2012 Uncategorized Comments Off on Simulations Plus (SLP) Signs Collaboration Agreement

NTS Realty Holdings (NLP) Partnership Announces Second Quarter Distribution

LOUISVILLE, KY — (Marketwire) — 06/13/12 — (NYSE MKT: NLP) (NYSE Amex: NLP) — NTS Realty Holdings Limited Partnership (the “Company”) announced today that the board of directors of its managing general partner, NTS Realty Capital, Inc., approved a quarterly distribution of $0.05 per unit on the Company’s limited partnership units. The distribution will be paid on July 13, 2012 to limited partners of record at the close of business on June 29, 2012. Distributions to limited partners are made in accordance with the Company’s distribution policy as described in its most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 23, 2012.

A spokesperson for the Company indicated that “The Company expects to continue its conservative philosophy with respect to distributions throughout 2012, and the amount of any future distributions will be subject to the performance of the Company’s properties, its potential acquisitions and dispositions, the need for cash reserves, capital expenditures and other factors, including, but not limited to, the continued volatility being exhibited in the global financial markets and the U.S. economy. In addition, the actual amount and timing of all future distributions must be approved by the managing general partner’s board of directors.”

About NTS Realty Holdings Limited Partnership

The Company currently owns, wholly, as a tenant in common with unaffiliated co-owners, or through joint venture investments with affiliated and unaffiliated third parties, twenty-four properties comprised of fifteen multifamily properties, seven office buildings and business centers and two retail properties. The properties are located in and around Louisville and Lexington, Kentucky, Nashville and Cordova, Tennessee, Richmond, Virginia, Fort Lauderdale and Orlando, Florida, Indianapolis, Indiana and Atlanta, Georgia. The Company’s limited partnership units are listed on the NYSE MKT platform under the trading symbol of “NLP.”

Forward Looking Statements

This press release contains forward looking statements that can be identified by the use of words like “believe,” “expect,” “may,” “could,” “intend,” “project,” “estimate,” or “anticipate.” These forward looking statements, implicitly or explicitly, include assumptions underlying the statements and other information with respect to the Company’s beliefs, plans, objectives, goals, expectations, estimates, intentions, financial condition, results of operations, future performance and business, including its expectation of, and estimates with respect to, revenues, expenses, earnings, return of and on equity, return on assets, asset quality and other financial data and performance ratios. Although the Company believes that the expectations reflected in its forward looking statements are reasonable, these statements involve risks and uncertainties which are subject to change based on various important factors, some of which are beyond the Company’s control. Important factors that would cause actual results to differ materially from expectations are disclosed under “Risk Factors” and elsewhere in the Company’s most recent annual report on Form 10-K, which was filed on March 23, 2012, and registration statement on Form S-4, which became effective on October 27, 2004.

If one or more of the factors affecting forward looking information and statements proves incorrect, the Company’s actual results of operations, financial condition or prospects could differ materially from those expressed in, or implied by, the forward looking information and statements contained in this press release.

Contact:
Gregory A. Wells
Executive Vice President and CFO
600 North Hurstbourne Parkway
Suite 300
Louisville, Kentucky 40222

Wednesday, June 13th, 2012 Uncategorized Comments Off on NTS Realty Holdings (NLP) Partnership Announces Second Quarter Distribution

Winland (WEX) Announces Receipt of Extension to Regain Compliance with NYSE Amex

Winland Electronics, Inc. (NYSE Amex: WEX) (“Winland”) announced that on April 11, 2012 it received notice from the NYSE Amex staff indicating that Winland is below certain of the NYSE Amex LLC’s (the “Exchange”) continued listing standards due to: stockholders’ equity of less than $4,000,000 and losses from continuing operations and/or net losses in three of its four most recent fiscal years, as set forth in Section 1003(a)(ii) of the Exchange’s Company Guide; and stockholders’ equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2011, as set forth in Section 1003(a)(iii) of the Exchange’s Company Guide. Winland was afforded the opportunity to submit a plan of compliance to the Exchange, and on May 11, 2012 Winland presented its plan to the Exchange. On June 11, 2012 the Exchange notified Winland that it accepted Winland’s plan of compliance and granted Winland an extension until May 29, 2013 to regain compliance with the continued listing standards. Winland will be subject to periodic review by the Exchange staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in Winland being delisted from the NYSE Amex Exchange.

About Winland Electronics

Winland Electronics, Inc. (www.winland.com) is an industry leader of critical condition monitoring devices. Products including EnviroAlert, WaterBug, TempAlert, Vehicle Alert and more are designed in-house to monitor critical conditions for industries including health/medical, grocery/food service, commercial/industrial, as well as agriculture and residential. Proudly made in the USA, Winland products are compatible with any hard wire or wireless alarm system and are available through distribution worldwide. Headquartered in Mankato, MN, Winland trades on the NYSE Amex Exchange under the symbol WEX.

Cautionary Statements

Certain statements contained in this press release and other written and oral statements made from time to time by Winland do not relate strictly to historical or current facts. As such, they are considered forward-looking statements, which provide current expectations or forecasts of future events. The statements included in this release with respect to meeting the Exchange’s continued listing standards by May 29, 2013 and that no other events will jeopardize Winland’s continued listing on the Exchange are forward-looking. No forward-looking statement can be guaranteed and actual results may vary materially.

Wednesday, June 13th, 2012 Uncategorized Comments Off on Winland (WEX) Announces Receipt of Extension to Regain Compliance with NYSE Amex

Mad Catz (MCZ) Reports Fiscal 2012 Q4 Net Sales of $29 Million

Mad Catz Interactive, Inc. (NYSE MKT/TSX: MCZ):

Conference Call: Today, June 13, 2012 at 5:00 p.m. ET
Dial-in numbers: (212) 231-2910 (U.S. & International)
Webcast: www.madcatz.com (Select “Investors”)
Replay Information: See text of the release

Mad Catz Interactive, Inc. (“Mad Catz” or “the Company”) (NYSE MKT/TSX: MCZ), today announced financial results for the fiscal fourth quarter and year ended March 31, 2012.

For the fiscal year ended March 31, 2012, the Company generated net sales of $117.6 million, a decline of 36% from record net sales of $184.0 million in fiscal 2011. Gross profit for fiscal 2012 declined 41% to $31.5 million, from $53.4 million in the prior fiscal year, while gross profit margin declined to 27%, compared to 29% in fiscal 2011. Total operating expenses in fiscal 2012 were $35.4 million, up 2% from $34.6 million in the prior year, leading to an operating loss of $3.9 million, compared to operating income of $18.8 million a year ago. Foreign exchange loss was $0.6 million, compared to a gain of $1.2 million in fiscal 2011. Reflecting an income tax benefit of $1.3 million, the Company recorded a net loss of $1.6 million, or a loss of $0.03 per share in the fiscal year ended March 31, 2012, compared to net income of $10.9 million, or $0.18 per diluted share in the prior fiscal year.

Adjusted EBITDA, a non-GAAP measure (defined as earnings before interest, taxes, depreciation and amortization and change in fair value of warrant liability), was a loss of $1.1 million in fiscal 2012, compared to a gain of $23.0 million in fiscal 2011. Adjusted net loss and adjusted loss per share, which exclude the impact of amortization of intangibles, stock-based compensation, change in warrant liability and goodwill impairment (if any), were $2.7 million and $0.04, respectively, in fiscal 2012, versus adjusted net income and adjusted net income (loss) per share of $12.4 million and $0.20, respectively, in fiscal 2011. A reconciliation of Adjusted EBITDA, adjusted net income (loss) and adjusted diluted earnings (loss) per share to the Company’s net income (loss) and net income loss per share is included in the financial tables accompanying this release.

For the fiscal fourth quarter ended March 31, 2012, Mad Catz reported net sales of $29.2 million, down 13% from $33.7 million in the fiscal 2011 fourth quarter. Gross profit for the March 2012 quarter declined 15% to $8.9 million from $10.5 million in the same quarter of the prior year while gross profit margin remained flat at 31%. Total operating expenses in the fiscal 2012 fourth quarter fell 4% to $8.5 million and the Company recorded operating income of $0.4 million, representing a decline of 76% from the $1.7 million generated in the comparable prior period. Foreign exchange loss was $0.2 million compared to a gain of $1.2 million in the fiscal 2011 fourth quarter. Reflecting an income tax benefit of $1.0 million, the Company reported net income of $0.8 million for the quarter ended March 31, 2012, or $0.01 per diluted share, versus net income of $1.5 million, or $0.03 per diluted share in the prior year fiscal fourth quarter.

Adjusted EBITDA was $1.1 million in the fourth quarter of fiscal 2012 compared to Adjusted EBITDA of $3.6 million in the prior year quarter. Adjusted net income and adjusted diluted earnings per share of $1.3 million and $0.02, respectively, in the fiscal fourth quarter of 2012 represented a reduction from adjusted net income and adjusted diluted earnings per share of $1.8 million and $0.03, respectively, in the same period a year ago.

Summary of Fiscal 2012 and Fourth Quarter Key Metrics:

  • Fiscal 2012 net sales decreased 36% to $117.6 million, while fiscal fourth quarter sales fell 13% to $29.2 million:
    • North American net sales decreased 49% to $57.4 million, and 35% to $13.9 million, in the fiscal 2012 full-year and fourth quarter periods, respectively. North American net sales represented 49% and 48% of full-year and quarterly net sales, respectively;
    • European net sales fell 18% to $54.5 million, and rose 14% to $12.7 million, in fiscal 2012 and in the fiscal 2012 fourth quarter, respectively. European net sales represented 46% and 43% of full-year and quarterly net sales, respectively; and,
    • Net sales to other countries increased 40% to $5.7 million, and 124% to $2.6 million, in the fiscal 2012 full-year and fourth quarter periods, respectively. Net sales to other countries represented 5% and 9% of full-year and quarterly net sales, respectively.
  • Gross sales by platform:
    • Xbox 360™ products accounted for 31% and 26% of sales in the fiscal 2012 full-year and fourth quarter, versus 31% and 24% in the respective prior year periods;
    • PC and Mac product sales were 28% and 32% of sales in the fiscal 2012 full-year and fourth quarter, versus 15% and 24% a year ago, respectively;
    • PS3 products sales accounted for 8% and 14% of fiscal 2012 full-year and fourth quarter sales, versus 17% and 13% in the respective prior year periods;
    • Wii products represented 3% and 1% of fiscal 2012 full-year and fourth quarter sales versus 14% and 8% in the prior year periods, respectively;
    • Handheld platform products were 2% and 1% of sales in the fiscal 2012 full-year and fourth quarter periods, versus 3% and 4% in the prior year’s respective periods; and,
    • All other platforms accounted for 28% and 26% of fiscal 2012 full-year and fourth quarter sales, versus 20% and 27% in the respective prior year periods.
  • Gross sales by category:
    • Audio products accounted for 38% and 37% of fiscal 2012 full-year and fourth quarter sales, versus 27% and 30% of sales in the prior year periods, respectively;
    • Specialty controllers accounted for 25% and 28% of sales in the fiscal 2012 full-year and fourth quarter, versus 28% and 32% in the prior year periods, respectively;
    • PC and Mac input device sales were 15% and 18% of sales in the fiscal 2012 full-year and fourth quarter, versus 7% and 12% in the respective prior year periods; Controllers represented 10% and 5% of sales in the fiscal 2012 full-year and fourth quarter, versus 15% and 11% in the prior year periods, respectively;
    • Accessories sales were 10% of sales in both the fiscal 2012 full-year and fourth quarter, versus 12% and 13% in the respective prior year periods; and,
    • Game sales accounted for 2% of sales in both the full-year and fourth quarter of fiscal 2012, versus 11% and 2% in the respective prior year periods.
  • Gross sales by brand:
    • Mad Catz products represented 38% and 35% of sales in the fiscal 2012 full-year and fourth quarter, versus 61% and 49% in the respective prior year periods;
    • Tritton products accounted for 32% and 31% of sales in the fiscal 2012 full-year and fourth quarter, versus 14% and 23% in the prior year periods, respectively;
    • Cyborg sales were 16% and 19% of sales in the fiscal 2012 full-year and fourth quarter, versus 7% and 13% in the respective prior year periods;
    • Saitek products accounted for 10% of sales in both the fiscal 2012 full-year and fourth quarter, versus 6% and 9% of sales in the prior year periods, respectively;
    • Eclipse sales were 3% and 4% of sales both in the fiscal 2012 and fiscal 2012 full-year and fourth quarters, respectively, and,
    • Other branded sales accounted for less than 1% of sales in both the full-year and fourth quarter of fiscal 2012, versus 9% and 2% in the respective prior year periods.
  • Reported net position of bank loan less cash at March 31, 2012 of $14.2 million compared to $15.5 million as of December 31, 2011, and $1.7 million at March 31, 2011.

Highlights of New Products Shipped in Q4 of Fiscal 2012 and Subsequent to the Fiscal Year-End:

  • SOULCALIBUR V Arcade FightStick Soul Edition for the Xbox 360 and PS3;
  • Primer Wireless Stereo Headset for Xbox 360;
  • New range of licensed Tom Clancy’s Ghost Recon: Future Soldier products, including the Tom Clancy’s Ghost Recon: Future Soldier Pro GamePad and the Tom Clancy’s Ghost Recon: Future Soldier 7.1 Surround Sound Headset;
  • Licensed Major League Gaming Pro Circuit Controller for the Xbox 360 and PS3;
  • A range of products for the Street Fighter X Tekken Fighting Game on the Xbox 360 and PS3, including the Street Fighter X Tekken FightPad SD, the Street Fighter X Tekken Arcade FightStick PRO and the Street Fighter X Tekken Arcade FightStick; and,
  • The Cyborg M.M.O.7 Gaming Mouse for PC and Mac.

Highlights of Upcoming Product Launches:

  • Cyborg F.R.E.Q. 5 Pro Gaming Headset for PC and Mac;
  • TRITTON SwitchBlade Wireless Headset for PS3;
  • Licensed Major League Gaming Pro Circuit Controller accessories for the Xbox 360 and PS3, including custom FacePlate Kits, ProCable products, the FightPad ProModule, Analog Stick Spacers and Analog Cap Packs;
  • Tritton Kunai headsets for the Wii U, 3DS, PlayStation Vita and PS3; and,
  • New range of products for the Wii U console including the PowerUp ChargeDock and FlipStand Protective Cover.

Key Developments in Q4 of Fiscal 2012 and Subsequent to the Fiscal Year-End:

  • Signed license agreement with Sony Computer Entertainment Japan to manufacture and distribute products in Japan for use with the PS3 and PlayStation Vita;
  • Announced a sponsorship agreement with the Aeroshell Aerial Aerobatic Team to promote the Company’s Saitek pro-flight products and upcoming Damage Inc. Pacific Squadron WWII video game;
  • Signed sponsorship agreement with the Western Wolves Professional Gaming Team to promote the Company’s pro-gaming equipment, including the MLG Pro Circuit Controller, Tournament Edition FightSticks and TRITTON headsets; and,
  • Signed license agreement with Microsoft to produce and distribute a range of Halo 4 branded headsets.

Commenting on the results, Darren Richardson, President and Chief Executive Officer of Mad Catz, said, “Fiscal 2012 full year results largely reflect the difficult year-ago comparison which benefited from sales of products related to specific video games and revenue from a third party distribution agreement, which has since been discontinued. We also experienced delays in launching key products for the 2011 holiday season and were impacted by the overall economy and fundamental changes in the video game industry, highlighted by the transition of Nintendo’s Wii console and the move by many casual gamers to smartphones and tablets. Thus, while we are not satisfied with these results, we believe a simple comparison between fiscal 2012 and 2011 is not a fully accurate indicator of the Company’s direction and prospects.

“Three years ago, we made a strategic decision to shift our focus towards high-value products built for passionate, hard core consumers. This shift has not happened overnight and is still on-going. Initial success was evident in growing sales of our high-end Saitek flight products and, more recently, is demonstrated by our widely acclaimed Cyborg PC and Mac products as well as our Tritton premium audio products. Each of these three brands generated sales growth in fiscal 2012. In particular, the sales of Tritton products grew 48% to $37 million in net sales and the sales of Cyborg products grew 40% to $19 million in net sales.

“We also believe these premium products have much longer product life spans and offer the best path forward as the video game industry reaches another inflection point with many casual gamers moving to tablet and smartphone gaming, leaving hard core gamers who demand the best. We realize and understand that more sales of these key products are needed and we are committed to increasing our sales and marketing efforts to expand awareness of these products, while keeping a sharp eye on operating expenses.

“In addition to our focus on creating aspirational products over the past few years, we have also expanded our geographic footprint as we continue to build a worldwide sales and marketing team. As games increasingly cross geographic borders and the Internet allows worldwide on-line competition, the Company is committed to position itself as a leading provider of products that optimize the passionate video gamer’s performance on a global basis.

“We’re starting to realize the benefits of our investment in an expanded geographic footprint in the Asia Pacific Region. Sales to Other Countries accounted for 2% of net sales in fiscal 2011, 5% of sales in fiscal 2012, and 9% of sales in the fourth quarter of fiscal 2012. We were also pleased to see European sales overcome considerable market headwinds and a difficult comparison to return to double digit growth in the fiscal fourth quarter.

“In fiscal 2011, we benefited from discrete opportunities to partner with premium game titles. We will continue to look for such opportunities and pursue them when they make financial sense. However, we believe that the long-term growth and financial health of the Company depends on creating ‘must have’ products for passionate consumers that do not rely on outside forces for their success.”

“This quarter we’re seeing strong sales to date and are expecting all territories to return to growth in the first quarter of fiscal 2013. We are also excited about our pipeline of new products for the holiday season with some key product releases, including the highly anticipated Warhead headset, which we expect to begin mass production in the next few weeks and to make a positive contribution to fiscal 2013 second quarter sales. We are optimistic that the early launch of these key new products will contribute to our return to growth for fiscal 2013.”

Mr. Richardson concluded, “Looking ahead, we have a range of exciting initiatives that should benefit fiscal 2013 and beyond. Our line of audio products is going into wide distribution in the United States and is selling well in other parts of the world. We intend to increase marketing and awareness efforts for our universally acclaimed R.A.T. PC and Mac products and plan to further fill out the PC and Mac product range. We intend to continue to carefully select targeted software opportunities that pose manageable downside risk by complementing our hardware initiatives. We are also committed to supporting the professional gaming community and developing products that live up to their exacting demands.”

The Company will host a conference call and simultaneous webcast on June 13, 2012, at 5:00 p.m. ET, which can be accessed by dialing (212) 231-2910. Following its completion, a replay of the call can be accessed for 30 days at the Company’s Web site (www.madcatz.com, select “Investors”) or for 7 days via telephone at (800) 633-8284 (reservation #21595689) or, for International callers, at (402) 977-9140.

About Mad Catz

Mad Catz Interactive, Inc. (NYSE MKT/TSX: MCZ) is a global provider of innovative interactive entertainment products marketed under its Mad Catz® (gaming), Tritton® (audio), and Saitek® (simulation) brands. Mad Catz also develops flight simulation software through its internal ThunderHawk Studios™; operates flight simulation centers under its Saitek brand; publishes games under its Mad Catz brand; and distributes games and videogame products for third parties. Mad Catz distributes its products through most leading retailers offering interactive entertainment products and has offices in North America, Europe and Asia. For additional information please go to www.madcatz.com.

Social Media

Facebook: http://www.facebook.com/MadCatzInc
Twitter: http://twitter.com/MadCatzInc
YouTube: http://www.youtube.com/MadCatzCompany

Safe Harbor

This press release contains forward-looking statements about the Company’s business prospects that involve substantial risks and uncertainties. The Company assumes no obligation to update the forward-looking statements contained in this press release as a result of new information or future events or developments. You can identify these statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “should,” “plan,” “goal,” “believe,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Among the factors that could cause actual results to differ materially are the following: the ability to maintain or renew the Company’s licenses; competitive developments affecting the Company’s current products; first party price reductions; the ability to successfully market both new and existing products domestically and internationally; difficulties or delays in manufacturing; or a downturn in the market or industry. A further list and description of these risks, uncertainties and other matters can be found in the Company’s reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators.

MAD CATZ INTERACTIVE, INC.
Consolidated Statements of Operations
(unaudited, in thousands of US$, except share and per share data)
Three Months Ended Twelve Months Ended
March 31, March 31,
2012 2011 2012 2011
Net sales $ 29,154 $ 33,697 $ 117,570 $ 183,974
Cost of sales 20,260 23,178 86,052 130,605
Gross profit 8,894 10,519 31,518 53,369
Operating expenses:
Sales and marketing 3,846 3,327 15,313 14,316
General and administrative 2,978 3,204 12,411 13,794
Research and development 1,158 1,930 5,634 4,678
Acquisition related items 288 164 1,067 873
Amortization of intangibles 234 242 955 951
Total operating expenses 8,504 8,867 35,380 34,612
Operating income (loss) 390 1,652 (3,862 ) 18,757
Interest expense, net (305 ) (614 ) (1,123 ) (2,897 )
Foreign exchange gain (loss), net (222 ) 1,237 (560 ) 1,195
Change in fair value of warrant liability (139 ) 2,557
Other income 76 24 115 247
Income (loss) before income taxes (200 ) 2,299 (2,873 ) 17,302
Income tax (expense) benefit 1,008 (813 ) 1,259 (6,367 )
Net income (loss) $ 808 $ 1,486 $ (1,614 ) $ 10,935
Net income (loss) per share:
Basic $ 0.01 $ 0.03 $ (0.03 ) $ 0.20
Diluted $ 0.01 $ 0.03 $ (0.03 ) $ 0.18
Weighted average number of common shares outstanding:
Basic 63,462,399 56,257,384 63,094,422 55,429,673
Diluted 64,106,597 70,262,793 63,094,422 66,924,206
MAD CATZ INTERACTIVE, INC.
Consolidated Balance Sheets
(unaudited in thousands of US$)
March 31, March 31,
2012 2011
Assets
Current assets:
Cash $ 2,474 $ 3,734
Accounts receivable, net 15,531 19,846
Other receivables 1,196 329
Inventories 32,521 27,978
Deferred tax assets 110 85
Income tax receivable 1,747
Other current assets 3,305 2,343
Total current assets 56,884 54,315
Deferred tax assets 440 590
Other assets 863 639
Property and equipment, net 4,037 3,921
Intangible assets, net 4,626 5,606
Goodwill 10,476 10,463
Total assets $ 77,326 $ 75,534
Liabilities and Shareholders’ Equity
Current liabilities:
Bank loan $ 16,654 $ 5,408
Accounts payable 17,634 13,700
Accrued liabilities 6,401 11,048
Convertible notes payable 14,500
Contingent consideration, current 1,600 1,542
Income taxes payable 1,375 1,918
Total current liabilities 43,664 48,116
Contingent consideration 2,769 2,897
Warrant liability 693
Deferred tax liabilities 245
Other long-term liabilities 211 424
Total liabilities 47,582 51,437
Shareholders’ equity:
Common stock, no par value, unlimited shares authorized; 63,462,399 shares issued and outstanding at March 31, 2012 and 57,029,350 issued and outstanding at March 31, 2011 59,432 50,648
Accumulated other comprehensive loss (1,533 ) (10 )
Accumulated deficit (28,155 ) (26,541 )
Total shareholders’ equity 29,744 24,097
Total liabilities and shareholders’ equity $ 77,326 $ 75,534

Geographical Sales Data

The Company’s net sales were generated in the following geographic regions:

Three Months Ended Year Ended
March 31, March 31,
2012 2011 2012 2011
Net sales
United States $ 12,805 $ 20,216 $ 53,565 $ 107,528
Europe 12,663 11,114 54,512 66,834
Canada 1,101 1,215 3,816 5,547
Other countries 2,585 1,152 5,677 4,065
$ 29,154 $ 33,697 $ 117,570 $ 183,974
MAD CATZ INTERACTIVE, INC.
Supplementary Data
(unaudited, in thousands of US$)
Adjusted Net Income (Loss) Reconciliation (non GAAP)
Three Months Ended Year Ended
March 31, March 31,
2012 2011 2012 2011
Pre-tax income (loss) $ (200 ) $ 2,299 $ (2,873 ) $ 17,302
Amortization of intangible assets 234 242 955 951
Stock-based compensation cost 181 145 649 603
Change in fair value of warrant liability 139 (2,557 )
Adjusted pre-tax income (loss)* 354 2,686 (3,826 ) 18,856
Adjusted provision for income taxes (at effective rate)* (942 ) 922 (1,145 ) 6,500
Adjusted net income (loss)* $ 1,296 $ 1,764 $ (2,681 ) $ 12,356
Adjusted diluted income (loss) per share* $ 0.02 $ 0.03 ($0.04 ) $ 0.20
*Adjusted net income and adjusted diluted earnings per share are non-GAAP financial measures and are not intended to be considered in isolation from, as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. Mad Catz believes that certain non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding the Company’s performance by excluding certain items that may not be indicative of the Company’s core business, operating results or future outlook. Mad Catz’ management uses, and believes that investors benefit from referring to, these non-GAAP financial measures in assessing the Company’s operating results, as well as when planning, forecasting and analyzing future periods. These non-GAAP measures, specifically those that adjust for stock-based compensation and amortization of intangibles, also facilitate comparisons of the Company’s performance to prior periods.
EBITDA and Adjusted EBITDA Reconciliation (non GAAP)
Three Months Ended Year Ended
March 31, March 31,
2012 2011 2012 2011
Net income (loss) $ 808 $ 1,486 $ (1,614 ) $ 10,935
Adjustments:
Interest expense 305 613 1,123 2,897
Income tax expense (benefit) (1,008 ) 813 (1,259 ) 6,367
Depreciation and amortization 822 727 3,253 2,764
EBITDA $ 927 $ 3,639 $ 1,503 $ 22,963
Change in fair value of warrant liability 139 (2,557 )
Adjusted EBITDA (loss) $ 1,066 $ 3,639 $ (1,054 ) $ 22,963

EBITDA, a non-GAAP financial measure, represents net income (loss) before interest, taxes, depreciation and amortization. To address the Warrants issued in the first quarter of fiscal 2012 and the resulting gain/loss on the change in the related warrant liability, we have excluded this non-operating, non-cash charge and defined the result as “Adjusted EBITDA”. We believe this to be a more meaningful measurement of performance than the previously calculated Adjusted EBITDA. Adjusted EBITDA is not intended to represent cash flows for the period, nor is it being presented as an alternative to operating income or net income as an indicator of operating performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with accounting principles generally accepted in the United States. As defined, Adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the method of calculation. We believe, however, that in addition to the operating performance measures found in our financial statements, Adjusted EBITDA is a useful financial performance measurement for assessing our Company’s operating performance. Our management uses Adjusted EBITDA as a measurement of operating performance in comparing our performance on a consistent basis over prior periods, as it removes from operating results the impact of our capital structure, including the interest expense resulting from our outstanding debt, and our asset base, including depreciation and amortization of our capital and intangible assets. In addition Adjusted EBITDA is an important measure for our lender.

Wednesday, June 13th, 2012 Uncategorized Comments Off on Mad Catz (MCZ) Reports Fiscal 2012 Q4 Net Sales of $29 Million

Biostar (BSPM) and Fmmu to Jointly Conduct Phases I To III Clinical Trials for Viacom Drug

XIANYANG, China, June 13, 2012 /PRNewswire-Asia/ — Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or “the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that it signed a Letter of Intent (“LOI”) with The Fourth Military Medical University (“FMMU”) to jointly conduct Phases I to III clinical trials for Viacom Pine II Cream (“Viacom”) drug. The LOI has been submitted to China’s military authorities for approval.

Viacom is a prescription drug developed by the First Affiliated Hospital of Dermatology of FMMU specifically for the needs of China’s military and will be used to treat skin diseases such as bacterial and fungal infections, dermatitis and eczema. Viacom has passed all standard tests related to quality, stability, toxicology and efficiency. Phases I to III clinical trials must be conducted for a period of three years prior to receiving final approval from military authorities to start production.

FMMU is one of China’s most prestigious military medical universities and research centers and its primary purpose is to advance China’s military medicine. In January 2012, Biostar was one of nine PRC pharmaceutical companies selected to cooperate with FMMU in the fields of research and product development.

According to the terms of the LOI, FMMU will be responsible for:

  • Submitting applications and receiving approvals to commence clinical trials; coordinating with China’s military authorities during clinical trials and securing all needed approvals to continue Phases I to III of these clinical trials for the next three years at FMMU’s facilities; securing final production approvals by October 2015; and providing the technology to ensure the quality and effectiveness of the product.

Biostar will be responsible for:

  • Coordinating with FMMU to complete the clinical trials before October 2015; bearing all costs of clinical trials and approvals; completing the construction of the production line and obtaining the GMP certification on time; and manufacturing the drug using the technology provided by FMMU.

Ronghua Wang, Biostar’s Chief Executive Officer and Chairman, commented, “Following the initial clinical research, Viacom has demonstrated encouraging results for the treatment of several skin diseases such as bacterial and fungal infections, dermatitis and eczema which are common among members of the PRC armed forces. Additionally, these types of skin diseases affect a large portion of China’s population and, if not treated properly, could result in severe health complications. Once Viacom receives approval from the military authorities to be sold in military hospitals, we will apply to receive SFDA’s approval to sell it in health care centers and hospitals all over the country.”

Mr. Wang continued, “This LOI follows the Cooperation Agreement we signed in January 2012, according to which Biostar was selected to work with FMMU’s staff to share resources and ideas and to carry out Phases I to IV of clinical trials for products which, when approved, will be sold directly to China’s military and to the three hospitals managed by FMMU. We are targeting additional LOIs with FMMU to conduct clinical trials for new products, which will help us become a production base for manufacturing drugs specifically for the needs of China’s military.”

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as “guidance,” “forecasted,” “projects,” “is expected,” “remain confident,” “will” and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company’s ability to complete the contemplated clinical trials and capitalize on this opportunity, the state of consumer confidence and market demand or the Company’s products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:

BioStar Pharmaceuticals, Inc.

The Equity Group, Inc.

Zack Pan, CFO

Lena Cati

Tel: 405-996-8829

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

Wednesday, June 13th, 2012 Uncategorized Comments Off on Biostar (BSPM) and Fmmu to Jointly Conduct Phases I To III Clinical Trials for Viacom Drug

GlobalWise (GWIV) to Present at the Inaugural Marcum MicroCap Conference June 20th in NY City

COLUMBUS, OH — (Marketwire) — 06/13/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (the “Company”) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce the Company will present at the Marcum MicroCap Conference on June 20th in New York City at the Roosevelt Hotel.

The event is held by Marcum LLP, one of the top ten auditors of U.S. public companies, and co-presented by CCG Investor Relations, a global investor relations consulting firm.

Presentation Details

  • Date: Wednesday, June 20, 2012
  • Time: 11:00am – 11:30am in the Promenade Suite
  • Location: The Roosevelt Hotel, 45 East 45th Street, New York, NY

Presenting on behalf of GlobalWise will be CEO William J. “BJ” Santiago and CTO Matthew Chretien.

The Marcum MicroCap conference is designed for investors interested in the micro-cap arena, and is expected to gather over 500 participants, including institutional investors, mutual funds, hedge funds, wealth managers and family offices. The conference will also feature panels on subjects highly relevant to small-cap corporate finance. The event is free to attend for qualified investors and the company will make a formal presentation and be available for one-on-ones.

For full event details and registration information, please click here.

About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top firms in the nation, Marcum offers the resources of more than 1,100 professionals, including more than 150 partners, in 23 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman, China and Hong Kong. The Firm’s presence runs deep with full service offices strategically located in major business markets. Marcum is a member of the Marcum Group, the gateway to a group of organizations that provide a variety of professional services including accounting and advisory, technology solutions, recruiting and wealth management. These organizations include Marcum LLP; Marcum Technology LLC; MarcumBuchanan Associates LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Cronus Partners LLC; Marcum Bernstein and Pinchuk LLP; and Marcum Healthcare LLC.

About CCG Investor Relations
CCG is a leading global investor relations and strategic communications consulting firm. In business for more than 30 years, the agency provides a complete range of investor communications, counseling, and IT and data solutions through a global network to over 100 clients across multiple capital markets. CCG has been awarded a number of industry honors for its handling of complex investor relations and crisis communications matters. The agency’s corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, London and Tel Aviv. For further information, contact CCG directly, or visit the Company’s web sites at http://www.ccgir.com/ and http://www.ccgirasia.com

About GlobalWise Investments, Inc.
GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975

Wednesday, June 13th, 2012 Uncategorized Comments Off on GlobalWise (GWIV) to Present at the Inaugural Marcum MicroCap Conference June 20th in NY City

Orexigen (OREX) and Roche Look to Take Advantage of Lucrative Anti-Obesity Drug Market

NEW YORK, NY — (Marketwire) — 06/12/12 — Despite growing global economic concerns the Biotech Industry has shown investors striking gains in 2012. The SPDR S&P Biotech ETF (XBI) is up over 23 percent year-to-date, nearly 10 times the 2.75 percent gain from Dow Jones over the same period. The anti-obesity drug market has been a hot topic recently as companies race to bring the first weight loss pill to market in nearly 13 years. Five Star Equities examines the outlook for companies in Biotech Industry and provides equity research on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Roche Holding Ltd. (PINKSHEETS: RHHBY).

Access to the full company reports can be found at:

www.FiveStarEquities.com/OREX

www.FiveStarEquities.com/RHHBY

Obesity in the U.S. has become a major problem. According to the National Institute of Health in 2009-2010 35.7 percent of adults in the U.S. were obese. On average it is estimated that an obese person spends $1,429 more normal-weight individuals. In 2003, it was estimated that as much as $75 billion of the nation’s public health cost was associated with obesity. If something is not done to slow down U.S. obesity rates it is predicted that obesity related spending will rise to $343 billion in 2018 according to numbers from the National Institute of Health.

Five Star Equities releases regular market updates on companies in the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Orexigen’s Contrave is an investigational medication for the treatment of obesity. With its unique mechanism of action in the CNS, Contrave has the potential to change the way obesity is treated by initiating weight loss by reducing appetite and increasing metabolism. Also by allowing the body to sustain continued weight loss by offsetting its natural tendency to fight back and slow down the weight loss process and addressing the reward system in the brain that causes food cravings.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche’s Xenical was the last weight-loss drug approved by the FDA in 1999.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.FiveStarEquities.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Five Star Equities

Tuesday, June 12th, 2012 Uncategorized Comments Off on Orexigen (OREX) and Roche Look to Take Advantage of Lucrative Anti-Obesity Drug Market

Reed’s, Inc. (REED) Initiates New Private Label Customer

LOS ANGELES, CA — (Marketwire) — 06/12/12 — Reed’s, Inc. (NASDAQ: REED), maker of the top-selling sodas in natural food stores nationwide, announced today that it has secured a private label partnership with one of the largest supermarket chains in the country.

“This is very exciting news. It demonstrates confidence in our company’s ability to produce unique, natural beverages for supermarket chains around the country,” stated Chris Reed, Founder and CEO of Reed’s, Inc. “The addition of this incremental private label business will further improve critical mass with respect to logistics, and strategically strengthen our partnership with respect to our branded products. We know from experience that once we have our foot in the door and have a chance to prove ourselves, we will be able to leverage this relationship into a more prosperous branded business, while positioning ourselves to gain more beverage lines in the private label category.”

About Reed’s, Inc.

Reed’s, Inc. makes the top-selling natural sodas in the natural foods industry sold in over 13,000 natural food markets and supermarkets nationwide. Its six award-winning non-alcoholic Ginger Brews are unique in the beverage industry, being brewed, not manufactured and using fresh ginger, spices and fruits in a brewing process that predates commercial soft drinks. The Company owns the top-selling root beer line in natural foods, the Virgil’s Root Beer product line, and the top-selling cola line in natural foods, the China Cola product line.

Other product lines include: Reed’s Ginger Candies and Reed’s Ginger Ice Creams. In 2009, Reed’s started producing private label natural beverages for select national chains. Reed’s products are sold through specialty gourmet and natural food stores, mainstream supermarket chains, retail stores and restaurants nationwide, and in Canada, as well as through private label relationships with major supermarket chains.

For more information about Reed’s, please visit the Company’s website at: http://www.reedsinc.com or call 800-99-REEDS.

Follow Reed’s on Twitter at http://twitter.com/reedsgingerbrew

Reed’s Facebook Fan Page at https://www.facebook.com/ReedsGingerBrew

SAFE HARBOR STATEMENT

Some portions of this press release, particularly those describing Reed’s goals and strategies, contain “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe future plans, objectives or goals are also forward-looking statements. While Reed’s is working to achieve those goals and strategies, actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These risks and uncertainties include difficulty in marketing its products and services, maintaining and protecting brand recognition, the need for significant capital, dependence on third party distributors, dependence on third party brewers, increasing costs of fuel and freight, protection of intellectual property, competition and other factors, any of which could have an adverse effect on the business plans of Reed’s, its reputation in the industry or its expected financial return from operations and results of operations. In light of significant risks and uncertainties inherent in forward-looking statements included herein, the inclusion of such statements should not be regarded as a representation by Reed’s that they will achieve such forward-looking statements. For further details and a discussion of these and other risks and uncertainties, please see our most recent reports on Form 10-KSB and Form 10-Q, as filed with the Securities and Exchange Commission, as they may be amended from time to time. Reed’s undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Investor Relations Contact:
Reed’s Inc.
(310)217-9400
Email: Email Contact

Tuesday, June 12th, 2012 Uncategorized Comments Off on Reed’s, Inc. (REED) Initiates New Private Label Customer
Top Small Cap Market News